Biogen Inc
(NASDAQ:BIIB)

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to ...

Website: http://www.biogen.com

Founded: 1978

Full Time Employees: 7,400

Sector: Healthcare

Industry: Drug Manufacturers-General

Pharmaceuticals Alzheimer's

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31

revenue:
product revenue	1,752,300,000	1,667,300,000	1,846,900,000	1,878,700,000	1,726,500,000
revenue from anti-cd20 therapeutic programs	419,100,000	521,200,000	493,900,000	467,300,000	378,200,000	465,200,000	446,200,000	444,500,000	394,000,000	435,800,000	420,900,000	433,400,000	399,500,000	447,900,000	416,900,000	436,300,000	399,400,000	414,100,000	415,400,000	440,000,000	389,000,000
alzheimer's collaboration revenue	59,500,000	47,100,000	42,700,000	54,900,000	33,000,000
contract manufacturing, royalty and other revenue	246,900,000	43,800,000	151,200,000	244,600,000	293,300,000	97,000,000	250,200,000	120,800,000	184,600,000	118,100,000	304,200,000	197,500,000	319,100,000
total revenue	2,477,800,000	2,279,400,000	2,534,700,000	2,645,500,000	2,431,000,000	2,454,700,000	2,465,800,000	2,464,900,000	2,290,500,000	2,386,300,000	2,530,300,000	2,456,000,000	2,463,000,000	2,544,000,000	2,508,500,000	2,589,100,000	2,531,800,000	2,733,800,000	2,778,900,000	2,775,000,000	2,694,000,000	2,852,600,000	3,376,100,000	3,681,600,000	3,534,300,000	3,671,300,000	3,600,100,000	3,616,700,000	3,489,800,000	3,526,300,000	3,439,000,000	3,356,500,000	3,131,100,000	3,307,000,000	3,077,800,000	3,078,400,000	2,810,700,000	2,872,000,000	2,955,800,000	2,894,200,000	2,726,800,000	2,839,336,000	2,777,859,000	2,591,642,000	2,554,963,000	2,640,675,000	2,511,446,000	2,421,452,000	2,129,751,000	1,965,850,000	1,827,780,000	1,723,473,000	1,415,096,000	1,417,941,000	1,385,554,000	1,420,951,000	1,292,014,000	3,738,700,000	1,309,934,000	1,208,647,000	1,203,342,000		1,175,800,000	1,212,702,000	1,108,860,000	3,256,830,000	1,120,518,000	1,093,289,000	1,036,484,000	1,068,913,000	1,092,964,000	993,444,000	942,186,000	893,300,000	789,231,000	773,176,000	715,910,000	708,341,000	703,492,000	660,041,000	611,175,000	632,853,000	596,211,000	605,634,000	587,802,000
yoy	1.93%	-7.14%	2.79%	7.33%	6.13%	2.87%	-2.55%	0.36%	-7.00%	-6.20%	0.87%	-5.14%	-2.72%	-6.94%	-9.73%	-6.70%	-6.02%	-4.16%	-17.69%	-24.63%	-23.78%	-22.30%	-6.22%	1.79%	1.28%	4.11%	4.68%	7.75%	11.46%	6.63%	11.74%	9.03%	11.40%	15.15%	4.13%	6.36%	3.08%	1.15%	6.41%	11.67%	6.73%	7.52%	10.61%	7.03%	19.97%	34.33%	37.40%	40.50%	50.50%	38.64%	31.92%	21.29%	9.53%	-62.07%	5.77%	17.57%	7.37%		11.41%	-0.33%	8.52%		4.93%	10.92%	6.98%	204.69%	2.52%	10.05%	10.01%	19.66%	38.48%	28.49%	31.61%	26.11%	12.19%	17.14%	17.14%	11.93%	17.99%	8.98%	3.98%
qoq	8.70%	-10.07%	-4.19%	8.82%	-0.97%	-0.45%	0.04%	7.61%	-4.01%	-5.69%	3.03%	-0.28%	-3.18%	1.42%	-3.11%	2.26%	-7.39%	-1.62%	0.14%	3.01%	-5.56%	-15.51%	-8.30%	4.17%	-3.73%	1.98%	-0.46%	3.64%	-1.04%	2.54%	2.46%	7.20%	-5.32%	7.45%	-0.02%	9.52%	-2.13%	-2.84%	2.13%	6.14%	-3.96%	2.21%	7.19%	1.44%	-3.25%	5.15%	3.72%	13.70%	8.34%	7.55%	6.05%	21.79%	-0.20%	2.34%	-2.49%	9.98%	-65.44%	185.41%	8.38%	0.44%			-3.04%	9.36%	-65.95%	190.65%	2.49%	5.48%	-3.03%	-2.20%	10.02%	5.44%	5.47%	13.19%	2.08%	8.00%	1.07%	0.69%	6.58%	8.00%	-3.43%	6.15%	-1.56%	3.03%
cost and expense:
cost of sales, excluding amortization and impairment of acquired intangible assets	661,000,000	495,500,000	674,400,000	605,000,000	629,300,000	583,500,000	638,700,000	546,000,000	542,200,000	618,300,000	659,600,000	592,700,000	662,800,000	570,900,000	469,500,000	484,000,000	753,900,000	660,100,000	511,800,000	459,700,000	478,100,000	490,600,000	449,100,000	411,100,000	454,300,000	447,100,000	430,000,000	476,300,000	602,000,000
research and development	539,000,000	509,400,000	436,100,000	399,000,000	434,100,000	532,300,000	542,700,000	513,900,000	452,900,000	570,900,000	736,300,000	584,200,000	570,600,000	601,600,000	549,200,000	528,600,000	551,700,000	699,500,000	702,400,000	585,100,000	514,200,000	1,726,100,000	1,140,900,000	647,600,000	476,300,000	691,700,000	540,400,000	484,800,000	563,700,000	611,600,000	507,900,000	981,000,000	496,700,000	587,600,000	446,400,000	796,200,000	423,400,000	533,900,000	529,000,000	473,100,000	437,300,000	541,660,000	519,863,000	490,728,000	460,549,000	500,091,000	417,174,000	447,273,000	528,884,000	422,233,000	410,017,000	327,463,000	284,340,000	345,181,000	304,217,000	329,559,000	355,962,000	918,211,000	301,391,000	285,644,000	293,633,000			331,675,000	307,030,000	979,013,000	304,055,000	416,453,000	279,478,000	292,767,000	268,800,000	252,259,000	258,232,000	229,292,000	286,274,000	218,149,000	191,449,000	199,480,000	211,033,000	161,985,000	145,892,000	168,314,000	227,039,000	179,843,000	178,784,000
acquired in-process research and development, upfront and milestone expense	34,000,000	222,400,000	2,100,000	46,600,000	200,700,000
selling, general and administrative	607,300,000	682,500,000	594,800,000	583,800,000	572,500,000	680,000,000	588,400,000	553,800,000	581,500,000	608,500,000	788,200,000	548,000,000	605,000,000	632,800,000	563,300,000	572,600,000	634,900,000	787,900,000	654,100,000	637,300,000	595,000,000	806,200,000	573,100,000	555,100,000	570,100,000	664,900,000	554,500,000	587,600,000	567,700,000	591,100,000	497,700,000	516,200,000	501,300,000	572,400,000	433,800,000	430,200,000	499,100,000	495,500,000	462,700,000	492,400,000	497,300,000	583,017,000	477,827,000	491,895,000	560,361,000	573,610,000	570,436,000	576,622,000	511,674,000	522,857,000	405,584,000	431,012,000	352,598,000	375,977,000	299,631,000	301,767,000	300,089,000	794,735,000	261,398,000	266,301,000	244,516,000			262,322,000	248,664,000	684,279,000	226,755,000	220,829,000	221,830,000	230,963,000	232,824,000	245,689,000	215,829,000	193,730,000	190,644,000	203,668,000	188,061,000	192,234,000	168,153,000	170,289,000	154,391,000	169,121,000	161,410,000	155,754,000	158,458,000
amortization and impairment of acquired intangible assets	136,500,000	136,600,000	135,700,000	130,900,000	111,800,000	151,200,000	130,300,000	86,900,000	78,300,000	76,600,000	60,900,000	52,900,000	50,200,000	175,000,000	56,500,000	67,500,000	66,900,000	68,100,000	111,000,000	604,100,000	98,100,000	249,200,000	82,600,000	61,500,000	71,500,000	67,700,000	283,900,000	70,100,000	68,200,000
collaboration profit sharing/	74,200,000	69,900,000	87,200,000	75,000,000	58,100,000	57,100,000	69,300,000	62,400,000	65,600,000	54,300,000	50,500,000	56,900,000	57,100,000
loss on fair value remeasurement of contingent consideration	20,500,000	5,200,000	5,600,000	13,200,000	9,600,000	3,900,000	23,800,000							-195,400,000	-2,100,000	-4,500,000	-7,100,000	-1,600,000	-15,600,000	300,000	-33,800,000	-62,800,000	-29,000,000	10,000,000				-20,000,000	11,500,000	-22,900,000	-87,900,000	1,900,000	-5,600,000
restructuring charges	7,900,000	6,600,000	7,400,000	-700,000	35,300,000	5,300,000	6,800,000	6,600,000	11,500,000	98,800,000	76,000,000	34,400,000	9,600,000	7,000,000	15,400,000	70,600,000	38,100,000										300,000	800,000	400,000	2,800,000	6,000,000	1,600,000	1,600,000					11,800,000	11,600,000		9,700,000
other expense	19,700,000	154,400,000	34,100,000	48,700,000	68,400,000	149,900,000	14,800,000	85,200,000	93,700,000	67,300,000	300,000,000	-121,200,000	69,400,000	113,100,000	-56,000,000	-428,600,000
total cost and expense	2,100,100,000	2,335,400,000	1,977,400,000	1,901,500,000	2,119,800,000	2,163,200,000	2,014,800,000	1,766,200,000	1,825,700,000	2,094,700,000	2,671,500,000	1,747,900,000	2,024,700,000	1,940,200,000	1,137,400,000	1,319,600,000	1,921,100,000	2,146,700,000	1,984,900,000	2,289,300,000	1,720,100,000
income before income tax expense	377,700,000	-56,000,000	557,300,000	744,000,000	311,200,000	403,625,000	451,000,000	698,700,000	464,800,000																																																384,514,000	1,230,448,000	480,766,000	399,085,000	426,234,000			396,892,000	295,303,000	939,141,000	393,538,000	237,594,000	311,804,000	214,708,250	321,125,000	291,334,000	246,374,000
income tax expense	58,200,000	-7,100,000	90,800,000	109,200,000	70,700,000	24,800,000	62,500,000	115,100,000	71,400,000	42,700,000	-72,900,000	114,800,000	50,700,000	54,300,000	236,200,000	216,700,000	125,600,000	443,200,000	-25,900,000	-409,100,000	44,200,000	13,300,000	240,800,000	446,100,000	292,000,000	276,100,000	211,300,000	248,100,000	422,500,000	469,600,000	369,800,000	263,700,000	322,500,000	1,566,100,000	383,800,000	269,600,000	239,200,000	190,300,000	337,000,000	353,600,000	356,400,000	257,125,000	330,093,000	292,501,000	281,881,000	268,233,000	274,774,000	268,521,000	178,414,000	190,261,000	186,105,000	159,140,000	65,508,000	136,341,000	131,044,000	121,021,000	82,148,000	317,424,000	127,104,000	95,036,000	117,468,000			102,243,000	75,310,000	241,681,000	113,936,000	92,709,000	65,225,000	83,456,000	114,337,000	84,706,000	83,277,000	93,911,000	54,733,000	51,886,000	71,893,000	72,515,000	63,048,000	70,404,000
net income attributable to biogen inc.	319,500,000	-48,900,000	466,500,000	634,800,000	240,500,000	266,700,000	388,500,000	583,600,000	393,400,000	249,700,000	-68,100,000	591,600,000	387,900,000	550,400,000	1,134,700,000	1,058,000,000	303,800,000	368,200,000	329,200,000	448,500,000	410,200,000	357,900,000	701,500,000	1,542,100,000	1,399,100,000	1,439,700,000	1,545,900,000	1,494,100,000	1,408,800,000	946,800,000	1,444,400,000	866,600,000	1,172,900,000	-297,400,000	1,226,100,000	862,800,000	747,600,000	649,200,000	1,032,900,000	1,049,800,000	970,900,000	831,561,000	965,622,000	927,276,000	822,541,000
net income per share
basic earnings per share attributable to biogen inc.	2.17	-0.33	3.18	4.33	1.65	1.83	2.67	4.01	2.71	1.72	-0.47	4.09	2.69	3.84	7.86	7.25	2.06	2.51	2.22	3	2.7	2.57	4.47	9.6	8.1	8.09	8.4	7.85	7.17	4.77	7.17	4.18	5.55	-1.38	5.8	4.07	3.47	3.01	4.72	4.79	4.44	3.78	4.16	3.94	3.5
diluted earnings per share attributable to biogen inc.	2.15	-0.35	3.17	4.33	1.64	1.83	2.66	4	2.7	1.71	-0.47	4.07	2.67	3.8	7.84	7.24	2.06	2.5	2.22	2.99	2.69	2.55	4.46	9.59	8.08	8.07	8.39	7.85	7.15	4.75	7.15	4.18	5.54	-1.38	5.79	4.07	3.46	3.01	4.71	4.79	4.43	3.77	4.15	3.93	3.49
weighted-average shares used for eps calculation																																																														254.9
gain on sale of priority review voucher								-88,600,000
product						1,345,225,000	1,769,400,000	1,899,600,000	1,711,900,000	1,353,575,000	1,805,200,000	1,845,800,000	1,763,300,000	1,904,500,000	1,962,100,000	2,054,900,000	2,066,300,000	2,193,500,000	2,205,700,000	2,236,000,000	2,211,700,000	2,301,600,000	2,690,300,000	2,795,700,000	2,904,600,000	2,924,800,000	2,894,700,000	2,880,300,000	2,680,000,000	2,825,700,000	2,780,100,000	2,757,500,000	2,523,500,000	2,712,400,000	2,622,500,000	2,639,700,000	2,380,100,000	2,502,900,000	2,539,600,000	2,466,000,000	2,309,400,000	2,425,895,000	2,391,717,000	2,198,566,000	2,172,322,000	2,286,981,000	2,117,366,000	2,056,292,000	1,742,765,000	1,607,080,000	1,453,554,000	1,385,918,000	1,095,779,000	1,074,676,000	1,039,110,000	1,076,800,000	975,488,000	2,860,360,000	975,757,000	956,703,000	907,102,000			859,235,000	824,220,000	2,351,252,000	801,689,000	790,970,000	733,409,000	731,835,000	758,260,000	684,486,000	665,070,000	604,227,000	529,581,000	518,625,000	484,388,000	463,617,000	475,096,000	436,081,000	406,519,000	429,231,000	391,366,000	398,822,000	397,584,000
net income						266,700,000	388,500,000	583,600,000	393,400,000	248,900,000	-68,300,000	593,300,000	387,600,000	549,500,000	1,134,900,000	1,058,700,000	218,500,000	-20,500,000	318,100,000	1,025,500,000	404,600,000	357,600,000	703,900,000	1,606,500,000	1,392,600,000	1,439,700,000	1,545,900,000	1,494,100,000	1,408,800,000	944,900,000	1,442,900,000	915,000,000	1,171,200,000	-166,300,000	1,226,100,000	862,800,000	747,500,000	647,900,000	1,030,200,000	1,048,400,000	969,200,000	828,708,000	1,019,493,000	924,825,000	820,174,000	882,585,000	856,120,000	723,132,000	479,728,000	457,306,000	487,616,000	490,670,000	426,749,000	292,127,000	398,400,000	387,141,000	302,366,000	913,024,000	353,662,000	304,049,000	308,766,000			294,649,000	219,993,000	697,460,000	279,602,000	144,885,000	246,579,000	206,654,000	206,788,000	206,628,000	163,097,000	201,150,000	119,381,000	186,140,000	131,501,000	108,556,000	156,599,000	-170,613,000	122,969,000	55,562,000	27,185,000	34,504,000	43,458,000
yoy						7.15%	-668.81%	-1.63%	1.50%	-54.70%	-106.02%	-43.96%	77.39%	-2780.49%	256.77%	3.24%	-46.00%	-105.73%	-54.81%	-36.17%	-70.95%	-75.16%	-54.47%	7.52%	-1.15%	52.37%	7.14%	63.29%	20.29%	-668.19%	17.68%	6.05%	56.68%	-125.67%	19.02%	-17.70%	-22.87%	-21.82%	1.05%	13.36%	18.17%	-6.10%	19.08%	27.89%	70.97%	93.00%	75.57%	47.38%	12.41%	56.54%	22.39%	26.74%	41.14%	-68.00%	12.65%	27.33%	-2.07%			3.19%	40.35%			103.37%	-10.78%	237.50%	35.21%	-29.88%	51.19%	2.74%	73.22%	11.01%	24.03%	85.30%	-23.77%	-209.10%	6.94%	95.38%	476.05%	-594.47%	182.96%
qoq						-31.35%	-33.43%	48.35%	58.06%	-464.42%	-111.51%	53.07%	-29.46%	-51.58%	7.20%	384.53%	-1165.85%	-106.44%	-68.98%	153.46%	13.14%	-49.20%	-56.18%	15.36%	-3.27%	-6.87%	3.47%	6.05%	49.10%	-34.51%	57.69%	-21.88%	-804.27%	-113.56%	42.11%	15.42%	15.37%	-37.11%	-1.74%	8.17%	16.95%	-18.71%	10.24%	12.76%	-7.07%	3.09%	18.39%	50.74%	4.90%	-6.22%	-0.62%	14.98%	46.08%	-26.67%	2.91%	28.04%	-66.88%	158.16%	16.32%	-1.53%				33.94%	-68.46%	149.45%	92.98%	-41.24%	19.32%	-0.06%	0.08%	26.69%	-18.92%	68.49%	-35.86%	41.55%	21.14%	-30.68%	-191.79%	-238.74%	121.32%	104.38%	-21.21%	-20.60%
net income margin %	0%	0%	0%	0%	0%	10.86%	15.76%	23.68%	17.18%	10.43%	-2.70%	24.16%	15.74%	21.60%	45.24%	40.89%	8.63%	-0.75%	11.45%	36.95%	15.02%	12.54%	20.85%	43.64%	39.40%	39.21%	42.94%	41.31%	40.37%	26.80%	41.96%	27.26%	37.41%	-5.03%	39.84%	28.03%	26.59%	22.56%	34.85%	36.22%	35.54%	29.19%	36.70%	35.68%	32.10%	33.42%	34.09%	29.86%	22.53%	23.26%	26.68%	28.47%	30.16%	20.60%	28.75%	27.25%	23.40%	24.42%	27.00%	25.16%	25.66%	NaN%	0%	24.30%	19.84%	21.42%	24.95%	13.25%	23.79%	19.33%	18.92%	20.80%	17.31%	22.52%	15.13%	24.07%	18.37%	15.33%	22.26%	-25.85%	20.12%	8.78%	4.56%	5.70%	7.39%
net income attributable to noncontrolling interests, net of tax										-800,000	-200,000	1,700,000	-300,000	-900,000	200,000	700,000	-85,300,000	-388,700,000	-11,100,000	577,000,000	-5,600,000	-300,000	2,400,000	64,400,000	-6,500,000					-1,900,000	-1,500,000	48,400,000	-1,700,000	131,100,000			-100,000	-1,300,000	-2,700,000	-1,400,000	-1,700,000	-2,853,000	53,871,000	-2,451,000	-2,367,000	-879,000	-738,000	8,626,000	-228,000							295,000	-295,000	30,422,000	1,836,000	16,015,000	14,435,000
gain on sale of building															-503,700,000
income before income tax expense and equity in loss of investee, net of tax										291,600,000	-141,200,000	708,100,000	438,300,000	603,800,000	1,371,100,000	1,269,500,000	347,400,000	405,000,000	291,100,000	582,100,000	467,000,000	352,900,000	957,800,000	2,037,500,000	1,699,400,000	1,728,400,000	1,779,000,000	1,758,500,000	1,860,000,000	1,414,500,000	1,812,700,000	1,178,700,000	1,493,700,000	1,399,800,000	1,609,900,000	1,132,400,000	986,700,000	838,200,000	1,367,200,000	1,402,000,000	1,325,600,000	1,085,785,000	1,356,419,000	1,222,207,000	1,102,889,000	1,151,012,000	1,136,288,000	993,586,000	665,747,000	652,521,000	679,891,000	652,099,000	496,068,000	431,217,000	530,702,000	508,673,000
equity in loss of investee, net of tax																-5,900,000	3,300,000	-17,700,000	-1,100,000	-34,300,000	18,200,000	-18,000,000	13,100,000	-15,100,000	14,800,000	12,600,000	21,800,000	16,300,000	28,700,000													-48,000	6,833,000	4,881,000	834,000	194,000	5,394,000	1,933,000	7,605,000	4,954,000	6,170,000	2,289,000	3,811,000	2,749,000	1,258,000	511,000
revenue from leqembi collaboration												-20,700,000	-18,900,000
other														191,600,000	129,500,000	97,900,000	66,100,000	126,200,000	157,800,000	99,000,000	93,300,000	132,000,000	125,700,000	407,600,000	109,300,000	145,700,000	109,600,000	160,000,000	292,400,000	165,700,000	147,200,000	108,600,000	164,400,000	179,600,000	48,800,000	41,600,000	90,000,000	50,900,000	98,600,000	79,000,000	87,900,000	79,543,000	48,961,000	55,566,000	52,030,000	49,164,000	103,402,000	61,864,000	90,101,000	89,354,000	71,016,000	48,770,000	54,711,000	62,317,000	58,652,000	59,521,000	31,974,000	148,214,000	67,706,000	35,486,000	40,116,000			47,096,000	29,712,000								29,893,000	18,333,000	25,013,000	23,961,000	24,358,000
collaboration profit sharing														35,200,000	45,300,000	29,400,000	-117,300,000	-67,300,000	21,200,000	-15,200,000	68,500,000	66,400,000	73,000,000	21,800,000	71,800,000	59,800,000	60,200,000	63,500,000	58,100,000	55,800,000	47,500,000	39,200,000	42,500,000	29,800,000	35,200,000	26,500,000	20,800,000	11,100,000	4,700,000	-5,600,000													85,357,000	77,944,000	75,545,000	78,511,000	85,894,000	236,296,000	81,475,000	88,050,000	74,794,000			62,692,000	63,557,000	155,207,000	60,697,000	49,138,000	42,773,000	37,673,000	43,533,000	33,429,000	21,406,000	13,909,000	5,842,000	-105,000	-5,567,000
acquired in-process research and development																				18,000,000					75,000,000						27,500,000	75,000,000	10,000,000			120,000,000																													39,976,000									35,808,000	29,959,000		18,405,000			330,520,000
income from operations																	610,700,000	587,100,000	794,000,000	485,700,000	973,900,000	-330,600,000	1,086,400,000	1,974,500,000	1,819,900,000	1,777,700,000	1,806,300,000	1,955,900,000	1,502,700,000	1,443,100,000	1,697,600,000	1,213,200,000	1,534,700,000	1,465,800,000	1,653,500,000	1,200,600,000	1,024,300,000	886,200,000	1,425,300,000	1,460,500,000	1,378,400,000	1,168,197,000	1,371,832,000	1,233,096,000	1,117,875,000	1,159,763,000	1,152,578,000	988,725,000	671,348,000	657,926,000	684,531,000	662,527,000	510,525,000	445,507,000	535,250,000	505,723,000	369,370,000	1,236,198,000	488,493,000	410,813,000	416,283,000		194,100,000	395,880,000	303,689,000	911,249,000	384,178,000	222,914,000	304,958,000	324,960,000	345,850,000	296,797,000	246,004,000	262,430,000	129,210,000	206,440,000	181,692,000	191,718,000	197,328,000	-122,015,000	172,989,000	93,299,000	21,165,000	46,301,000	75,274,000
yoy																	-37.29%	-277.59%	-26.91%	-75.40%	-46.49%	-118.60%	-39.85%	0.95%	21.11%	23.19%	6.40%	61.22%	-2.09%	-1.55%	2.67%	1.05%	49.83%	65.40%	16.01%	-17.80%	-25.69%	-24.14%	3.90%	18.44%	23.31%	0.73%	19.02%	24.72%	66.51%	76.28%	68.37%	49.24%	31.50%	47.68%	27.89%	31.01%	38.22%	-63.96%	9.57%	23.10%	-11.27%		151.67%	3.77%	37.08%		-49.48%	77.59%	-0.42%	180.42%	11.08%	-24.89%	23.96%	23.83%	167.67%	43.77%	35.40%	36.88%	-34.52%	-269.19%	5.03%	105.49%	832.33%	-363.53%	129.81%
qoq																	4.02%	-26.06%	63.48%	-50.13%	-394.59%	-130.43%	-44.98%	8.49%	2.37%	-1.58%	-7.65%	30.16%	4.13%	-14.99%	39.93%	-20.95%	4.70%	-11.35%	37.72%	17.21%	15.58%	-37.82%	-2.41%	5.96%	17.99%	-14.84%	11.25%	10.31%	-3.61%	0.62%	16.57%	47.27%	2.04%	-3.89%	3.32%	29.77%	14.59%	-16.77%	5.84%	36.92%	-70.12%	153.06%	18.91%	-1.31%			-50.97%	30.36%	-66.67%	137.19%	72.34%	-26.90%	-6.16%	-6.04%	16.53%	20.65%	-6.26%	103.10%	-37.41%	13.62%	-5.23%	-2.84%	-261.72%	-170.53%	85.41%	340.82%	-54.29%	-38.49%
operating margin %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	24.12%	21.48%	28.57%	17.50%	36.15%	-11.59%	32.18%	53.63%	51.49%	48.42%	50.17%	54.08%	43.06%	40.92%	49.36%	36.14%	49.01%	44.32%	53.72%	39.00%	36.44%	30.86%	48.22%	50.46%	50.55%	41.14%	49.38%	47.58%	43.75%	43.92%	45.89%	40.83%	31.52%	33.47%	37.45%	38.44%	36.08%	31.42%	38.63%	35.59%	28.59%	33.06%	37.29%	33.99%	34.59%	NaN%	16.51%	32.64%	27.39%	27.98%	34.29%	20.39%	29.42%	30.40%	31.64%	29.88%	26.11%	29.38%	16.37%	26.70%	25.38%	27.07%	28.05%	-18.49%	28.30%	14.74%	3.55%	7.65%	12.81%
other income																	-263,300,000	-182,100,000	-502,900,000	96,400,000	-506,900,000	683,500,000	-128,600,000	63,000,000	-120,500,000	-49,300,000	-27,300,000	-197,400,000	357,300,000	-28,600,000	115,100,000	-34,500,000	-41,000,000	-66,000,000	-43,600,000	-68,200,000	-37,600,000	-48,000,000	-58,100,000	-58,500,000	-52,800,000	-82,412,000	-15,413,000	-10,889,000	-14,986,000	-8,751,000	-16,290,000	4,861,000	-5,601,000	-5,405,000	-4,640,000	-10,428,000	-14,457,000	-14,290,000	-4,548,000	2,950,000	15,144,000	-5,750,000	-7,727,000	-11,728,000	9,951,000			1,012,000	-8,386,000	27,892,000	9,360,000	14,680,000	6,846,000	-34,850,000	-24,725,000	-5,463,000	370,000	32,631,000	44,904,000	31,586,000	21,702,000	-10,647,000	22,319,000	21,806,000	18,665,000	11,837,000	11,192,000	6,051,000	-8,926,000
revenues:
revenues from anti-cd20 therapeutic programs																						419,000,000	560,100,000	478,300,000	520,400,000	600,800,000	595,800,000	576,400,000	517,400,000	534,900,000	511,700,000	490,400,000	443,200,000	415,000,000	406,500,000	397,100,000	340,600,000	318,200,000	317,600,000	349,200,000	329,500,000
cost and expenses:
loss on divestiture of hillerød, denmark manufacturing operations																										-40,200,000	-17,700,000
total cost and expenses																						3,183,200,000	2,289,700,000	1,707,100,000	1,714,400,000	1,893,600,000	1,793,800,000	1,660,800,000	1,987,100,000	2,083,200,000	1,741,400,000	2,143,300,000	1,596,400,000	1,841,200,000	1,424,300,000	1,877,800,000	1,786,400,000	1,985,800,000	1,530,500,000	1,433,700,000	1,348,400,000	1,671,139,000	1,406,027,000	1,358,546,000	1,437,088,000	1,485,532,000	1,363,247,000	1,436,627,000	1,462,262,000	1,315,503,000	1,150,198,000	1,066,265,000	909,622,000	987,507,000	882,023,000	915,228,000	922,644,000	2,502,502,000	821,441,000	797,834,000	787,059,000
(gain) loss on fair value remeasurement of contingent consideration																									-4,600,000	2,600,000	-57,800,000							15,300,000	30,000,000	21,200,000	10,000,000	4,700,000	5,900,000	10,600,000	2,300,000	24,613,000	244,000	-2,201,000	7,844,000	7,320,000	-49,433,000	4,019,000	-799,000	2,436,000	-97,000	-5,163,000
loss on assets and liabilities held for sale																												-2,300,000	115,500,000
cost of sales, excluding amortization of acquired intangible assets																														331,950,000	460,800,000	421,000,000	446,000,000	509,200,000	370,000,000	366,200,000	384,600,000	378,500,000	416,900,000	370,300,000	313,000,000	331,821,000	310,028,000	286,120,000	312,431,000	297,265,000	302,639,000	291,887,000	279,245,000	258,553,000	234,696,000	230,728,000	133,749,000	133,828,000	139,358,000	139,112,000	133,197,000	343,253,000	123,527,000	100,503,000	103,113,000			106,985,000	97,055,000	288,618,000	93,486,000	90,721,000	98,197,000	101,161,000	107,493,000	92,401,000	100,934,000	87,566,000	81,613,000	84,063,000	81,950,000
amortization of acquired intangible assets																														123,300,000	281,900,000	107,400,000	103,900,000	139,800,000	108,900,000	117,500,000	448,500,000	104,200,000	99,700,000	92,900,000	88,800,000	96,628,000	98,065,000	92,004,000	95,903,000	107,246,000	122,431,000	116,826,000	143,258,000	109,424,000	99,998,000	82,225,000	51,301,000	50,948,000	53,013,000	52,282,000	45,961,000	159,219,000	49,347,000	55,136,000	53,216,000			53,148,000	48,889,000	238,464,000	51,347,000	93,234,000	89,248,000	90,631,000	94,464,000	72,869,000	74,781,000	70,925,000	65,689,000	60,961,000	59,920,000	60,020,000	60,011,000	76,260,000	70,707,000	73,559,000	75,990,000	77,078,000	75,677,000
unconsolidated joint business																																										333,898,000	337,181,000	337,510,000	330,611,000	304,530,000	290,678,000	303,296,000	296,885,000	269,416,000	303,210,000	288,785,000	264,606,000	280,948,000	287,792,000	284,630,000	284,552,000	730,126,000	266,471,000	216,458,000	256,124,000			306,371,000	254,928,000	810,944,000	283,919,000	275,570,000	278,818,000	303,214,000	298,979,000	278,822,000	247,223,000	253,707,000	234,637,000	230,590,000	207,164,000	217,568,000	203,820,000	206,095,000	183,380,000	131,746,000	181,597,000	184,934,000	160,453,000
gain on sale of rights																																														4,620,000	4,379,000	3,900,000	3,859,000	7,579,000	6,949,000	5,319,000	5,051,000	15,073,000	31,719,000
net income attributable to biogen idec inc.																																														883,464,000	856,858,000	714,506,000	479,956,000	457,306,000	487,616,000	490,670,000	426,749,000	292,127,000	398,400,000	386,846,000	302,661,000	882,602,000	351,826,000	288,034,000	294,331,000			293,438,000	217,442,000	692,469,000	277,663,000	142,845,000	243,987,000
basic earnings per share attributable to biogen idec inc.																																														3.75	3.63	3.02	2.03	1.93	2.06	2.07	1.8	1.24	1.68	1.62	1.26	3.64	1.45	1.19	1.22			1.13	0.8	2.41	0.96	0.49	0.85
diluted earnings per share attributable to biogen idec inc.																																														3.73	3.62	3.01	2.02	1.92	2.05	2.06	1.79	1.23	1.67	1.61	1.25	3.61	1.43	1.18	1.2			1.12	0.8	2.4	0.95	0.49	0.84
restructuring charge																																																							803,000	1,139,000	283,000	17,223,000	1,803,000		16,587,000
fair value adjustment of contingent consideration																																																					2,277,000	3,629,000	9,456,000	12,858,000	1,258,000	33,565,000	2,500,000	2,200,000	1,200,000
net income attributable to biogen idec																																																															254,100,000
diluted earnings per share attributable to biogen idec																																																															1.05
costs and expenses:
total costs and expenses																																																																816,822,000	805,171,000	2,345,581,000	736,340,000	870,375,000	731,526,000	743,953,000	747,114,000	696,647,000	696,182,000	630,870,000	660,021,000	566,736,000	534,218,000	516,623,000	506,164,000	782,056,000	438,186,000	539,554,000	575,046,000	559,333,000	512,528,000
net income attributable to noncontrolling interest, net of tax																																																																1,211,000	2,551,000	4,991,000	1,939,000	2,040,000	2,592,000
other revenues																																																																		8,727,500	34,910,000	26,749,000	24,257,000	33,864,000	35,725,000	30,136,000
in-process research and development																																																																						6,250,000			25,000,000
basic earnings per share																																																																						0.7	0.71	0.71	0.55	0.67	0.41	0.55	0.39	0.32	0.46	-0.5	0.36	0.17	0.08	0.1	0.13
diluted earnings per share																																																																						0.7	0.7	0.7	0.54	0.65	0.41	0.54	0.38	0.32	0.45	-0.5	0.36	0.16	0.08	0.1	0.12
facility impairments and gain on sale																																																																														-230,750	175,000
gain on settlement of license agreement																																																																														-8,548,000		-34,192,000
income before income tax provision and cumulative effect of accounting change																																																																										295,061,000	174,114,000	238,026,000				-100,209,000	191,654,000
income before cumulative effect of accounting change																																																																										201,150,000	119,381,000	186,140,000	131,501,000	108,556,000	156,599,000	-170,613,000	119,190,000
cumulative effect of accounting change, net of income tax																																																																														-3,778,999.99			3,779,000
basic earnings per share:
diluted earnings per share:
gain on sale of long lived assets
shares used in calculating:
gain on sale of long-lived assets
income before income tax expense and cumulative effect of accounting change																																																																													203,394,000	181,071,000	219,647,000
royalty																																																																														15,178,500	21,867,000	18,286,000	20,561,000
corporate partner																																																																														750,500	2,709,000	-421,000	715,000	132,000	131,000	144,000	3,016,000
cost of product revenues, excluding amortization of acquired intangible assets																																																																														52,298,750	65,742,000	77,060,000	66,391,000
cost of royalty revenues																																																																														771,250	1,050,000	933,000	1,103,000	1,237,000	1,203,000	849,000	1,128,000
facility impairments and loss on sale																																																																																-799,000	-298,000	15,208,000	21,046,000
income tax provision																																																																																	72,464,000	11,477,500	5,172,000
royalties																																																																																		21,593,000	23,117,000	21,734,000	26,749,000
cost of product revenues																																																																																		64,270,750	88,358,000	70,244,000	98,481,000
income before income tax provision																																																																																		37,764,750	32,357,000	52,352,000	66,348,000
loss on sale of manufacturing facility																																																																																				75,565,000
income tax benefit																																																																																				17,848,000	22,890,000

Balance Sheets:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2013-02-05	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31

assets
current assets:
cash and cash equivalents	3,382,700,000	3,008,500,000	3,862,800,000	2,758,800,000	2,598,300,000	2,375,000,000	1,699,200,000	1,908,900,000	1,074,400,000	1,049,900,000	2,287,900,000	2,617,800,000	2,898,200,000	3,419,300,000	3,675,600,000	2,646,600,000	1,749,300,000	2,261,400,000	1,541,800,000	1,742,000,000	1,217,500,000	1,331,200,000	2,224,800,000	2,384,900,000	2,591,300,000	2,343,900,000	1,723,400,000	2,243,200,000	2,386,700,000	1,250,200,000	4,108,000,000	1,573,800,000	1,548,100,000	1,169,500,000	924,000,000	2,326,500,000	2,084,800,000	1,362,000,000	1,130,700,000	1,308,000,000	4,089,003,000	1,282,078,000	1,478,051,000	1,204,924,000	1,186,281,000	863,197,000	828,601,000	602,562,000	427,811,000	392,507,000	663,302,000		570,721,000	451,723,000	456,811,000	298,139,000	514,542,000	575,140,000	697,526,000	790,675,000	759,598,000	626,800,000	720,962,000	639,559,000	581,889,000	585,788	786,804,000	764,104,000	622,385,000	1,010,701,000	466,493,000	688,499,000	659,662,000	437,326,000	1,611,581,000	780,940,000	661,377,000	414,594,000	345,104,000	535,865,000	568,168,000	296,492,000	638,400,000	276,443,000	209,447,000
current portion of marketable securities	900,000,000	807,200,000
accounts receivable	1,369,200,000	1,342,400,000	1,374,100,000	1,624,200,000	1,602,900,000	1,404,800,000	1,536,200,000	1,627,100,000	1,604,500,000	1,664,100,000	1,781,400,000	1,685,900,000	1,634,400,000	1,705,000,000	1,568,800,000	1,567,600,000	1,632,000,000	1,549,400,000	1,723,000,000	1,688,000,000	1,854,300,000	1,913,800,000	2,024,900,000	2,133,600,000	2,092,600,000	1,933,500,000	1,959,600,000	2,088,900,000	2,017,300,000	1,951,000,000	1,939,200,000	1,787,000,000	1,567,500,000	1,630,200,000	1,501,500,000	1,441,600,000	1,467,800,000	1,293,000,000	1,395,100,000	1,227,000,000	1,327,780,000	1,310,821,000	1,389,995,000	1,292,445,000	1,091,232,000	1,002,328,000	1,018,487,000	824,406,000	891,396,000	861,457,000	753,611,000		686,848,000	661,519,000	683,841,000	684,242,000	584,603,000	581,052,000	666,960,000	687,609,000	605,329,000		548,893,000	560,777,000	551,208,000	550,995	511,286,000	481,214,000	446,665,000	484,636,000	482,797,000	451,480,000	392,646,000	378,807,000	359,518,000	324,569,000	317,353,000	282,519,000	284,912,000	276,441,000		261,535,000	254,014,000	275,014,000
due from anti-cd20 therapeutic programs	421,200,000	524,600,000	475,900,000	459,800,000	393,600,000	464,000,000	451,900,000	451,100,000	395,200,000	435,900,000	428,300,000	438,100,000	393,800,000	431,400,000	415,400,000	435,900,000	389,400,000	412,300,000	400,000,000	422,200,000	369,800,000	413,500,000	527,200,000	441,100,000	511,600,000	582,300,000	557,500,000	527,100,000	508,400,000	481,900,000	553,500,000	532,600,000	518,000,000	502,900,000	324,500,000	300,600,000	305,200,000	334,100,000	315,100,000
inventory	1,949,000,000	2,168,100,000	2,209,400,000	2,274,300,000	2,273,900,000	2,460,500,000	2,469,200,000	2,506,100,000	2,516,800,000	2,527,400,000	2,982,400,000	1,333,500,000	1,281,000,000	1,344,400,000	1,375,000,000	1,294,200,000	1,215,400,000	1,351,500,000	1,347,900,000	1,254,800,000	1,171,800,000	1,068,600,000	1,027,700,000	952,700,000	858,800,000	751,800,000	776,700,000	770,200,000	916,600,000	931,700,000	890,800,000	902,700,000	1,007,200,000	936,500,000	921,600,000	1,001,600,000	1,009,700,000	996,400,000	964,600,000	893,400,000	918,921,000	865,738,000	825,349,000	804,022,000	753,063,000	715,935,000	672,750,000	659,003,000	614,483,000	570,390,000	506,557,000		447,373,000	392,936,000	362,940,000	337,619,000	326,843,000	310,934,000	308,254,000	295,260,000	289,066,000		267,878,000	280,038,000	293,950,000	278,686	268,529,000	268,076,000	263,602,000	249,858,000	255,028,000	237,172,000	233,987,000	222,857,000	207,897,000	186,220,000	169,102,000	155,119,000	147,024,000	191,022,000	182,815,000	227,469,000	243,538,000	236,624,000	251,016,000
other current assets	1,168,300,000	1,123,300,000	916,800,000	850,600,000	757,300,000	752,500,000	674,000,000	615,300,000	1,165,300,000	1,182,000,000	974,100,000	895,900,000	1,412,000,000	1,417,600,000	1,495,500,000	1,645,300,000	927,400,000	740,800,000	736,300,000	767,900,000	786,100,000	881,100,000	683,500,000	638,800,000	683,800,000	743,200,000	980,400,000	965,400,000	848,300,000	843,300,000	895,900,000	962,000,000	967,000,000	1,146,100,000	1,231,900,000	1,093,300,000	993,100,000	1,027,400,000	941,100,000	836,900,000	861,882,000	750,039,000	579,599,000	447,462,000	396,471,000	346,787,000	295,260,000	226,134,000	205,635,000	173,708,000	169,939,000		136,011,000	126,174,000	149,247,000	122,126,000	144,600,000	194,199,000	201,794,000	186,291,000	215,822,000		218,645,000	210,295,000	177,924,000	141,623	143,183,000	149,374,000	139,400,000	143,116,000	199,774,000	181,170,000	183,376,000	186,187,000	161,406,000	151,219,000	154,713,000	74,614,000	74,033,000	79,624,000	78,054,000	78,894,000	85,346,000	91,692,000	119,118,000
total current assets	9,190,400,000	8,974,100,000	8,936,600,000	7,967,700,000	7,626,000,000	7,456,800,000	6,830,500,000	7,108,500,000	6,756,200,000	6,859,300,000	8,454,100,000	10,431,700,000	9,762,500,000	9,791,200,000	9,765,800,000	9,740,900,000	7,915,900,000	7,856,500,000	7,162,300,000	7,183,700,000	6,719,500,000	6,887,100,000	7,843,100,000	8,493,800,000	8,007,200,000	8,448,200,000	7,909,800,000	8,942,600,000	8,719,000,000	7,432,100,000	10,195,400,000	7,873,300,000	7,568,000,000	7,108,700,000	6,859,700,000	8,732,200,000	8,091,800,000	7,447,700,000	7,201,300,000	6,700,300,000	9,270,873,000	5,618,985,000	5,258,896,000	4,672,673,000	4,372,111,000	3,925,013,000	3,525,024,000	3,184,934,000	2,643,672,000	2,523,221,000	5,328,838,000		3,244,337,000	3,055,388,000	2,868,919,000	2,677,950,000	2,975,427,000	2,837,288,000	2,688,623,000	2,628,315,000	2,540,420,000		2,255,231,000	2,409,012,000	2,480,595,000	2,572,259	2,744,278,000	2,480,653,000	2,458,000,000	2,639,080,000	2,161,028,000	2,140,475,000	2,368,407,000	1,620,470,000	2,694,006,000	1,941,341,000	1,712,567,000	1,385,157,000	1,449,740,000	1,595,681,000	1,618,081,000	1,535,212,000	1,796,302,000	1,983,727,000
marketable securities	465,600,000	431,900,000	97,600,000									3,460,500,000	2,143,100,000	1,473,500,000	1,235,500,000	2,151,300,000	2,002,400,000	1,541,100,000	1,413,300,000	1,308,800,000	1,320,000,000	1,278,900,000	1,355,000,000	1,942,700,000	1,269,100,000	2,093,500,000	1,228,800,000	1,665,800,000	2,041,700,000	1,974,000,000	1,808,000,000	2,115,200,000	1,960,200,000	1,723,500,000	1,956,200,000	2,568,600,000	2,231,200,000	2,434,800,000	2,454,700,000	2,120,500,000	1,753,499,000	1,086,595,000	673,946,000	640,460,000	675,065,000	709,869,000	431,610,000	620,167,000	240,882,000	275,163,000			1,134,989,000	1,154,071,000	949,239,000	978,473,000	1,176,115,000	944,381,000	629,218,000	437,870,000	448,146,000		248,710,000	513,115,000	681,835,000	821,888	836,270,000	637,219,000	719,586,000	217,127,000	234,515,000	156,920,000	319,408,000	234,021,000	191,136,000	346,639,000	241,314,000	246,425,000	368,670,000
property, plant and equipment	3,017,900,000	3,055,400,000	3,075,700,000	3,098,800,000	3,132,400,000	3,181,300,000	3,210,900,000	3,249,300,000	3,275,300,000	3,309,700,000	3,301,600,000	3,307,200,000	3,300,900,000	3,298,600,000	3,266,400,000	3,355,100,000	3,372,800,000	3,416,400,000	3,410,700,000	3,442,200,000	3,438,300,000	3,411,500,000	3,359,900,000	3,330,700,000	3,281,600,000	3,138,100,000	3,077,500,000	3,013,800,000	3,538,900,000	3,409,000,000	3,334,700,000	3,182,400,000	2,995,900,000	2,827,600,000	2,610,900,000	2,501,800,000	2,387,000,000	2,301,800,000	2,258,900,000	2,187,600,000	2,027,821,000	1,837,670,000	1,739,628,000	1,765,683,000	1,724,129,000	1,756,164,000	1,744,266,000	1,750,710,000	1,806,074,000	1,787,776,000	1,736,811,000		1,742,226,000	1,676,583,000	1,622,812,000	1,617,459,000	1,571,387,000	1,572,259,000	1,712,869,000	1,673,502,000	1,641,634,000		1,571,521,000	1,604,573,000	1,637,083,000	1,634,696	1,608,660,000	1,562,174,000	1,594,754,000	1,579,938,000	1,629,398,000	1,581,664,000	1,497,383,000	1,392,577,000	1,330,899,000	1,291,041,000
operating lease assets	251,300,000	265,400,000	330,500,000	334,500,000	346,400,000	356,400,000	380,400,000	389,400,000	428,100,000	420,000,000	460,900,000	366,500,000	399,100,000	403,900,000	424,500,000	321,100,000	359,000,000	375,400,000	389,100,000	402,500,000	414,500,000	433,300,000	434,200,000	436,200,000	422,000,000	422,000,000	434,400,000	447,800,000
intangible assets	9,053,500,000	9,178,500,000	9,331,900,000	9,467,500,000	9,584,600,000	9,691,200,000	9,805,500,000	8,232,900,000	8,284,700,000	8,363,000,000	7,344,600,000	1,776,400,000	1,813,300,000	1,850,100,000	2,008,900,000	2,075,300,000	2,150,800,000	2,221,300,000	2,286,800,000	2,385,000,000	2,988,100,000	3,084,300,000	3,323,600,000	3,383,800,000	3,446,900,000	3,392,400,000	3,681,300,000	3,056,200,000	3,379,000,000	3,661,300,000	3,794,500,000	3,879,600,000	4,019,400,000	4,051,300,000	4,103,900,000	3,808,300,000	3,869,900,000	3,967,600,000	4,012,200,000	4,085,100,000	4,181,245,000	4,294,791,000	4,353,123,000	4,028,507,000	4,129,754,000	4,249,378,000	4,364,384,000	4,474,653,000	4,580,199,000	4,678,884,000	1,581,511,000		1,631,547,000	1,681,232,000	1,732,972,000	1,783,981,000	1,608,191,000	1,659,114,000	1,678,867,000	1,731,844,000	1,772,826,000		1,768,929,000	1,822,133,000	1,871,078,000	1,927,115	1,978,519,000	2,071,809,000	2,161,058,000	2,250,766,000	2,347,561,000	2,421,255,000	2,492,354,000	2,562,566,000	2,626,838,000	2,688,090,000	2,747,241,000	2,795,620,000	2,856,292,000	2,904,838,000	2,975,601,000	3,057,209,000	3,139,315,000	3,216,772,000	3,292,827,000
goodwill	6,488,700,000	6,491,100,000	6,490,700,000	6,493,100,000	6,477,100,000	6,478,900,000	6,485,800,000	6,227,400,000	6,227,400,000	6,219,200,000	6,807,500,000	5,753,700,000	5,751,800,000	5,749,000,000	5,741,200,000	5,749,600,000	5,758,000,000	5,761,100,000	5,760,500,000	5,763,900,000	5,763,100,000	5,762,100,000	5,755,700,000	5,751,000,000	5,752,000,000	5,746,100,000	5,749,200,000	5,639,700,000	5,440,100,000	5,170,300,000	4,907,800,000	4,632,500,000	4,127,500,000	3,870,400,000	3,611,700,000	3,669,300,000	3,419,700,000	3,167,100,000	2,917,900,000	2,663,800,000	2,408,854,000	2,154,341,000	1,849,852,000	1,760,249,000	1,541,204,000	1,364,815,000	1,232,916,000	1,232,916,000	1,210,718,000	1,210,718,000	1,210,718,000		1,201,296,000	1,204,740,000	1,197,904,000	1,193,279,000	1,146,314,000	1,146,314,000	1,146,314,000	1,146,314,000	1,146,314,000		1,138,621,000	1,138,621,000	1,138,621,000	1,138,621	1,138,621,000	1,138,621,000	1,138,621,000	1,137,547,000	1,139,597,000	1,140,190,000	1,137,372,000	1,136,858,000	1,135,939,000	1,135,745,000	1,154,757,000	1,153,980,000	1,156,348,000	1,130,430,000	1,130,430,000	1,151,105,000	1,151,105,000	1,151,105,000	1,151,105,000
deferred tax asset	238,200,000	292,500,000	312,400,000	330,900,000	307,500,000	324,200,000	968,700,000	915,100,000	898,300,000	928,600,000	1,069,800,000	1,208,400,000	1,211,800,000	1,226,400,000	1,174,500,000	1,235,700,000	1,288,800,000	1,415,100,000	1,810,400,000	1,849,900,000	1,286,300,000	1,369,500,000	1,372,900,000	1,710,200,000	3,109,400,000	3,284,500,000	2,820,100,000	2,074,400,000
investments and other assets	777,500,000	750,600,000	729,700,000	637,700,000	559,100,000	560,500,000	631,400,000	681,500,000	697,600,000	745,000,000	754,600,000	1,104,900,000	1,380,800,000	1,529,200,000	1,612,600,000	1,500,800,000	1,767,500,000	1,939,500,000	2,018,600,000	2,528,100,000	2,423,000,000	2,899,000,000	1,834,900,000	1,483,300,000	1,130,600,000	1,238,800,000	1,306,000,000	1,898,300,000	1,009,800,000	902,100,000	380,100,000	1,027,500,000	1,300,400,000	1,268,300,000	1,184,500,000	1,335,800,000	1,239,600,000	1,153,000,000	1,094,600,000	1,107,600,000	892,221,000	751,588,000	640,630,000	618,795,000	565,513,000	611,791,000	639,269,000	594,350,000	636,028,000	533,852,000	306,839,000		274,054,000	271,144,000	271,864,000	368,937,000	331,548,000	237,870,000	211,747,000	228,105,000	248,198,000		201,730,000	210,761,000	230,397,000	256,299	259,507,000	261,074,000	235,152,000	210,695,000	204,198,000	212,540,000	201,028,000	181,910,000	230,630,000	267,697,000	245,620,000	232,913,000	233,004,000	293,768,000	264,061,000	270,341,000	157,828,000	148,203,000	155,933,000
total assets	29,483,100,000	29,439,500,000	29,207,500,000	28,330,200,000	28,033,100,000	28,049,300,000	28,313,200,000	26,804,100,000	26,567,600,000	26,844,800,000	28,193,200,000	25,156,800,000	24,598,400,000	24,554,100,000	24,854,200,000	25,081,400,000	23,614,400,000	23,877,300,000	23,806,700,000	24,470,400,000	23,854,700,000	24,618,900,000	24,934,100,000	25,511,800,000	26,119,200,000	27,484,000,000	26,287,600,000	26,445,500,000	25,492,200,000	23,952,900,000	26,090,100,000	23,652,600,000	23,073,200,000	21,759,000,000	21,195,900,000	22,876,800,000	22,104,900,000	21,514,800,000	20,674,700,000	19,504,800,000	20,728,368,000	16,759,171,000	15,219,454,000	14,316,559,000	13,704,142,000	12,917,998,000	12,230,131,000	11,863,335,000	11,250,249,000	10,841,590,000	10,164,717,000		10,130,118,000	9,630,621,000	9,162,380,000	9,113,549,000	9,049,604,000	8,802,204,000	8,621,979,000	8,293,524,000	8,092,493,000		7,502,150,000	8,217,323,000	8,551,854,000	9,026,437	8,777,196,000	8,575,206,000	8,478,991,000	8,535,208,000	8,172,826,000	8,170,653,000	8,628,815,000	7,816,375,000	8,935,715,000	8,709,580,000	8,552,808,000
liabilities and equity
current liabilities:
taxes payable	93,600,000	114,800,000	103,300,000	114,800,000	626,100,000	548,300,000	499,100,000	281,600,000	231,200,000	257,400,000	243,800,000	260,000,000	235,500,000	259,900,000	237,300,000	284,900,000	317,300,000	174,700,000	234,200,000	230,900,000	143,100,000	142,000,000	119,400,000	576,700,000	310,000,000	125,600,000	427,200,000	238,500,000	254,100,000	223,000,000	231,900,000	68,200,000	121,300,000	52,600,000	70,000,000	231,900,000	208,800,000	212,800,000	496,500,000	208,700,000	458,672,000	457,769,000	322,075,000	168,058,000	159,638,000	192,758,000	161,045,000	179,685,000	144,180,000	81,563,000	28,045,000		20,066,000	44,252,000	58,315,000	50,066,000	45,939,000	47,984,000	10,330,000	93,483,000	84,517,000		113,283,000	108,972,000	75,891,000	59,961	81,594,000	247,319,000	223,260,000	176,753,000	138,871,000	54,267,000	11,274,000		17,106,000	76,922,000	145,529,000	139,728,000	165,594,000	208,215,000		250,351,000	222,803,000	161,913,000
accounts payable	358,500,000	432,000,000	413,100,000	408,400,000	391,500,000	424,200,000	422,700,000	354,500,000	387,000,000	403,300,000	440,100,000	445,400,000	491,200,000	491,500,000	383,200,000	434,800,000	398,700,000	589,200,000	427,900,000	375,300,000	430,400,000	454,900,000	398,400,000	383,900,000	389,000,000	382,200,000	377,100,000	378,000,000	342,300,000	295,700,000	345,800,000	395,500,000	298,700,000	330,300,000	316,400,000	279,800,000	274,000,000	225,900,000	271,300,000	267,400,000	251,228,000	282,702,000	236,128,000	229,178,000	233,629,000	224,931,000	212,809,000	219,913,000	166,709,000	163,094,000	165,207,000		203,999,000	157,424,000	159,152,000	173,330,000	186,448,000	159,197,000	170,746,000	159,136,000	162,529,000		144,476,000	121,356,000	118,534,000	108,547	210,941,000	104,271,000	107,417,000	123,512,000	116,755,000	114,842,000	90,672,000	92,336,000	99,440,000	102,183,000	100,457,000	62,822,000	62,280,000	58,119,000	99,780,000	48,210,000	66,004,000	75,015,000	121,471,000
accrued expense and other	2,546,800,000	2,802,600,000	2,773,600,000	2,660,500,000	2,530,700,000	2,807,700,000	2,755,100,000	2,472,100,000	2,354,600,000	2,623,600,000	3,838,400,000	2,481,100,000	2,288,200,000	2,521,400,000	3,305,900,000	3,298,500,000	2,231,100,000	2,535,200,000	2,550,700,000	2,741,000,000	2,592,300,000
total current liabilities	2,998,900,000	3,349,400,000	3,290,000,000	3,183,700,000	5,297,400,000	5,528,800,000	5,425,000,000	3,108,200,000	3,222,800,000	3,434,300,000	5,022,300,000	3,186,500,000	3,014,900,000	3,272,800,000	3,926,400,000	5,018,000,000	3,946,600,000	4,298,200,000	4,211,600,000	3,347,200,000	3,165,800,000	3,742,200,000	3,804,000,000	3,447,100,000	4,638,600,000	4,432,200,000	3,210,900,000	3,148,700,000	3,174,900,000	3,152,400,000	3,152,100,000	3,368,200,000	3,448,400,000	3,379,700,000	2,992,500,000	3,419,900,000	2,499,700,000	2,516,200,000	2,776,600,000	2,577,700,000	2,633,968,000	2,555,832,000	1,946,231,000	2,219,706,000	1,940,647,000	1,916,624,000	1,594,247,000	1,758,279,000	1,518,711,000	1,304,074,000	1,281,662,000		1,657,389,000	1,521,093,000	1,432,865,000	1,337,319,000	912,889,000	885,346,000	954,330,000	978,846,000	1,050,122,000		755,658,000	682,330,000	714,942,000	721,368	803,926,000	807,767,000	923,222,000	985,872,000	885,441,000	707,172,000	2,189,175,000	1,988,744,000	3,464,929,000	500,448,000	582,855,000	495,010,000	499,982,000	520,797,000	583,036,000	558,945,000	540,653,000	1,228,529,000
notes payable	6,288,500,000	6,286,800,000	6,285,100,000	6,283,700,000	4,548,700,000							6,284,600,000	6,282,700,000	6,281,000,000	6,279,200,000	6,277,400,000	6,275,700,000	6,274,000,000	6,272,300,000	7,269,200,000	7,267,200,000	7,426,200,000	7,425,000,000	7,423,800,000	4,459,900,000	4,458,200,000	5,948,500,000	5,943,200,000	5,931,100,000	5,928,400,000	5,929,400,000											576,207,000	580,672,000	582,061,000	583,977,000	586,091,000	591,012,000																					1,082,909,000	1,085,431,000	1,042,427,000	1,038,086,000	1,060,448,000	51,843,000	50,113,000	51,348,000	52,043,000	96,694,000	45,074,000	44,526,000	43,978,000				751,681,000	748,430,000
deferred tax liability	483,500,000	507,600,000	358,100,000	118,300,000	133,200,000	190,500,000	882,400,000	590,600,000	658,100,000	641,800,000	728,100,000	143,900,000	251,300,000	334,700,000	328,900,000	480,600,000	571,200,000	694,500,000	774,700,000	918,900,000	966,700,000	1,032,800,000	1,123,400,000	1,461,500,000	2,722,800,000	2,820,400,000	2,400,600,000	1,741,700,000				122,600,000	120,700,000	100,800,000	94,500,000	93,100,000
long-term operating lease liabilities	273,400,000	290,400,000	305,000,000	310,900,000	323,400,000	334,500,000	357,000,000	367,500,000	406,500,000	400,000,000	428,800,000	304,400,000	327,000,000	333,000,000	354,800,000	274,200,000	312,300,000	330,400,000	348,200,000	363,900,000	380,000,000	402,000,000	409,100,000	414,800,000	403,700,000	410,500,000	423,000,000	436,100,000
other long-term liabilities	787,100,000	748,500,000	761,800,000	799,600,000	751,700,000	732,300,000	744,100,000	556,700,000	777,100,000	781,100,000	747,900,000	776,900,000	935,500,000	944,200,000	1,198,100,000	1,167,800,000	1,287,900,000	1,320,500,000	1,318,200,000	1,356,400,000	1,411,800,000	1,329,600,000	1,428,100,000	1,475,400,000	1,357,300,000	1,370,900,000	1,355,800,000	1,353,800,000	1,511,800,000	1,457,600,000	1,640,000,000	1,628,700,000	716,900,000	750,900,000	688,800,000	722,500,000	862,100,000	951,000,000	916,600,000	905,800,000	861,421,000	915,731,000	892,529,000	650,096,000	658,276,000	710,965,000	702,908,000	659,231,000	608,473,000	595,642,000	674,951,000		604,266,000	539,569,000	534,358,000	517,406,000	400,276,000	384,450,000	351,685,000	356,261,000	325,599,000		257,985,000	259,300,000	254,205,000	331,761	330,996,000	318,492,000	308,238,000	298,267,000	224,916,000	346,933,000	331,977,000	226,076,000	193,955,000	195,337,000	79,836,000	98,167,000	95,668,000	80,354,000	72,309,000	58,615,000	57,259,000	62,598,000	54,959,000
total liabilities	10,831,400,000	11,182,700,000	11,000,000,000	10,696,200,000	11,054,400,000	11,333,300,000	11,954,300,000	10,915,000,000	11,354,600,000	12,045,400,000	13,713,500,000	10,696,300,000	10,811,400,000	11,165,700,000	12,087,400,000	13,218,000,000	12,393,700,000	12,917,600,000	12,925,000,000	13,255,600,000	13,191,500,000	13,932,800,000	14,189,600,000	14,222,600,000	13,582,300,000	13,492,200,000	13,338,800,000	12,623,500,000	11,732,400,000	11,699,200,000	12,052,600,000	11,054,500,000	10,224,300,000	10,185,400,000	9,728,500,000	10,748,200,000	9,990,100,000	10,111,100,000	10,346,600,000	10,129,900,000	10,161,425,000	4,186,173,000	3,549,996,000	3,502,519,000	3,273,257,000	3,352,772,000	3,089,068,000	3,242,497,000	3,124,561,000	2,939,445,000	2,825,111,000		3,166,323,000	2,968,681,000	2,891,695,000	2,805,001,000	2,622,617,000	2,568,610,000	2,565,785,000	2,619,224,000	2,643,050,000		2,290,860,000	2,266,729,000	2,289,972,000	2,428,627	2,531,491,000	2,554,952,000	2,672,908,000	2,766,730,000	2,649,895,000	2,637,945,000	3,094,520,000	2,823,676,000	4,299,016,000	1,362,414,000	1,403,030,000
commitments, contingencies and guarantees
equity:
biogen inc. shareholders’ equity:
preferred stock, par value 0.001 per share...
common stock	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	100,000	124,000	129,000	129,000	129,000	129,000	128,000	128,000	128,000	128,000	128,000	128,000		127,000	127,000	127,000	129,000	128,000	128,000	127,000	125,000	124,000		129,000	139,000	144,000	149	149,000	149,000	149,000	149,000	149,000	149,000	147,000	146,000	172,000	173,000	173,000	173,000	173,000	173,000	173,000	175,000	175,000	173,000	173,000
additional paid-in capital	896,700,000	863,100,000	797,700,000	714,000,000	629,900,000	569,400,000	488,500,000	407,500,000	329,500,000	302,500,000	242,200,000	170,700,000	91,200,000	73,300,000			119,000,000	68,200,000							100,000				47,800,000			97,800,000	59,200,000	19,300,000				69,100,000	18,400,000		1,342,373,000	4,251,443,000	4,242,426,000	4,196,156,000	4,150,007,000	4,106,084,000	4,054,774,000	4,023,651,000	3,987,377,000	3,917,985,000	3,858,955,000		3,854,525,000	3,819,063,000	3,825,647,000	4,217,248,000	4,185,048,000	4,143,429,000	4,224,865,000	3,975,428,000	3,895,103,000		4,282,739,000	5,268,465,000	5,781,920,000	6,184,315	6,142,936,000	6,109,917,000	6,073,957,000	6,029,111,000	5,979,200,000	5,848,543,000	5,807,071,000	5,497,506,000	8,286,958,000	8,286,744,000	8,308,232,000	8,260,886,000	8,248,773,000	8,203,521,000	8,206,911,000	8,246,743,000	8,260,548,000	8,207,433,000	8,184,979,000
accumulated other comprehensive income	-140,200,000	-182,000,000	-214,800,000	-238,100,000	-174,500,000	-136,200,000	-145,700,000	-146,000,000	-160,500,000	-153,700,000	-159,300,000	-172,800,000	-172,000,000		-163,600,000	-110,400,000	-115,200,000																																				-55,305,000	-51,115,000	-50,557,000	-17,710,000	-26,535,000	7,571,000	25,713,000	-992,000	-21,610,000		-28,422,000	22,872,000	50,496,000	37,114	11,293,000	-32,346,000	-11,106,000	33,431,000	121,115,000	123,439,000	79,246,000	48,127,000	32,167,000	31,658,000	21,855,000		-22,532,000	4,594,000					-6,767,000
retained earnings	20,872,200,000	20,552,700,000	20,601,600,000	20,135,100,000	19,500,300,000	19,259,800,000	18,993,100,000	18,604,600,000	18,021,000,000	17,627,600,000	17,377,900,000	17,446,000,000	16,854,400,000	16,466,500,000	15,916,100,000	14,959,900,000	14,215,500,000	13,911,700,000	13,543,500,000	13,900,700,000	13,833,500,000	13,976,300,000	13,961,000,000	14,466,700,000	15,673,100,000	17,065,200,000	16,182,800,000	17,026,700,000	16,944,100,000	15,499,500,000	17,334,600,000	15,810,400,000	16,107,700,000	14,881,700,000	14,781,200,000	15,071,600,000	15,030,000,000	14,229,100,000	13,179,300,000	12,208,400,000	11,999,358,000	11,033,736,000	10,106,460,000	9,283,919,000	8,400,455,000	7,543,597,000	6,829,091,000	6,349,135,000	5,891,829,000	5,404,213,000	4,913,543,000		4,486,794,000	4,194,551,000	3,796,154,000	3,409,308,000	3,106,761,000	2,806,523,000	2,454,848,000	2,166,813,000	1,872,481,000		1,405,340,000	1,131,523,000	1,068,890,000	781,321	516,632,000	388,019,000	270,180,000	75,361,000
treasury stock	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,977,100,000	-2,611,700,000	-2,611,700,000	-2,611,700,000	-2,611,700,000	-2,611,700,000	-2,611,713,000	-2,611,706,000	-2,611,706,000	-2,611,706,000	-2,084,908,000	-2,061,832,000	-1,724,927,000	-1,724,927,000	-1,724,927,000	-1,365,641,000	-1,365,641,000		-1,324,618,000	-1,303,074,000	-1,303,074,000	-1,303,074,000	-839,903,000	-728,503,000	-728,503,000	-537,215,000	-349,592,000		-488,980,000	-513,627,000	-679,920,000	-438,710	-458,472,000	-478,045,000	-527,097,000	-369,574,000	-474,396,000	-240,219,000			-25,346,000	-150,194,000	-319,655,000
total equity	18,651,700,000	18,256,800,000	18,207,500,000	17,634,000,000	16,978,700,000	16,716,000,000	16,358,900,000	15,889,100,000	15,213,000,000	14,799,400,000	14,479,700,000	14,460,500,000	13,787,000,000	13,388,400,000	12,766,800,000	11,863,400,000	11,220,700,000	10,959,700,000	10,881,700,000	11,214,800,000	10,663,200,000	10,686,100,000	10,744,500,000	11,289,200,000	12,536,900,000	13,991,800,000	12,948,800,000	13,822,000,000	13,759,800,000	12,253,700,000	14,037,500,000	12,598,100,000	12,848,900,000	11,573,600,000	11,467,400,000	12,128,600,000	12,114,800,000	11,403,700,000	10,328,100,000	9,374,900,000	10,566,943,000	12,572,998,000	11,669,458,000	10,814,040,000	10,430,885,000	9,565,226,000	9,141,063,000	8,620,838,000	8,125,688,000	7,902,145,000	7,339,606,000		6,963,795,000	6,661,940,000	6,270,685,000	6,308,548,000	6,426,987,000	6,233,594,000	6,056,194,000	5,674,300,000	5,449,443,000					6,597,810	6,245,705,000
total liabilities and equity	29,483,100,000	29,439,500,000	29,207,500,000	28,330,200,000	28,033,100,000	28,049,300,000	28,313,200,000	26,804,100,000	26,567,600,000	26,844,800,000	28,193,200,000	25,156,800,000	24,598,400,000	24,554,100,000	24,854,200,000	25,081,400,000	23,614,400,000	23,877,300,000	23,806,700,000	24,470,400,000	23,854,700,000	24,618,900,000	24,934,100,000	25,511,800,000	26,119,200,000	27,484,000,000	26,287,600,000	26,445,500,000	25,492,200,000	23,952,900,000	26,090,100,000	23,652,600,000	23,073,200,000	21,759,000,000	21,195,900,000	22,876,800,000	22,104,900,000	21,514,800,000	20,674,700,000	19,504,800,000	20,728,368,000	16,759,171,000	15,219,454,000	14,316,559,000	13,704,142,000	12,917,998,000	12,230,131,000	11,863,335,000	11,250,249,000	10,841,590,000	10,164,717,000		10,130,118,000	9,630,621,000	9,162,380,000	9,113,549,000	9,049,604,000	8,802,204,000	8,621,979,000	8,293,524,000	8,092,493,000					9,026,437	8,777,196,000
current portion of notes payable					1,749,100,000											999,800,000	999,500,000	999,100,000	998,800,000						1,501,800,000	1,495,300,000					3,300,000											3,262,000	3,254,000	3,136,000	3,220,000																									10,215,000	11,544,000	12,841,000	1,511,135,000	1,510,113,000	11,897,000	9,148,000
current portion of notes payable and term loan						1,748,600,000
notes payable and term loan						4,547,200,000	4,545,800,000	6,292,000,000	6,290,100,000	6,788,200,000	6,786,400,000
biogen inc. shareholders’ equity
current portion notes payable and term loan							1,748,100,000
current portion of term loan									250,000,000	150,000,000	500,000,000
total biogen inc. shareholders’ equity										14,799,400,000	14,483,800,000	14,466,900,000	13,796,600,000	13,397,900,000	12,775,500,000	11,872,500,000	11,242,300,000	10,896,200,000	10,429,900,000	10,751,900,000	10,682,200,000	10,700,300,000	10,758,500,000	11,308,700,000	12,546,900,000	13,995,900,000	12,952,900,000	13,829,900,000	13,766,600,000	12,260,900,000	14,053,700,000	12,612,800,000	12,860,500,000	11,585,200,000	11,479,000,000	12,140,100,000	12,117,500,000	11,403,800,000	10,326,800,000	9,372,800,000	10,572,726,000	12,572,577,000	11,666,771,000
noncontrolling interests											-4,100,000	-6,400,000	-9,600,000	-9,500,000	-8,700,000	-9,100,000	-21,600,000	63,500,000	451,800,000	462,900,000	-19,000,000	-14,200,000	-14,000,000	-19,500,000	-10,000,000	-4,100,000	-4,100,000	-7,900,000	-6,800,000	-7,200,000	-16,200,000	-14,700,000	-11,600,000	-11,600,000	-11,600,000	-11,500,000	-2,700,000	-100,000	1,300,000	2,100,000	-5,783,000	421,000	2,687,000	5,030,000	3,189,000	3,927,000	4,352,000	596,000	596,000	596,000	596,000		2,272,000	2,388,000	2,388,000	2,647,000	1,488,000	4,446,000	79,144,000	70,141,000	52,937,000
accumulated other comprehensive loss														-164,900,000				-106,700,000	-136,600,000	-171,800,000	-174,300,000	-299,000,000	-225,500,000	-181,000,000	-149,300,000	-92,300,000	-252,900,000	-219,800,000	-248,300,000	-261,600,000	-303,900,000	-318,400,000	-329,400,000	-338,800,000	-325,200,000	-319,900,000	-300,900,000	-282,800,000	-259,300,000	-224,000,000	-157,416,000	-101,025,000	-70,538,000	-59,488,000	-37,987,000	-26,678,000	-22,355,000	-27,745,000	-29,315,000	-55,136,000	-67,975,000																											-17,876,000			-13,910,000	-6,189,000	-8,382,000	-9,377,000
commitments and contingencies
accrued expenses and other																						3,145,300,000	3,286,200,000	2,486,500,000	2,437,800,000	2,429,100,000	2,318,000,000	2,435,000,000	2,578,500,000	2,633,700,000	2,571,100,000	2,901,300,000	2,455,200,000	2,436,900,000	2,044,600,000	2,903,500,000	2,012,000,000	2,072,700,000	2,003,900,000	2,096,800,000	1,918,897,000	1,812,099,000	1,384,774,000	1,819,334,000	1,544,160,000	1,495,549,000	1,216,843,000	1,355,187,000	1,204,437,000	1,056,229,000	885,093,000		979,945,000	866,208,000	762,353,000	660,562,000	677,210,000	674,743,000	641,273,000	591,448,000	665,923,000		487,803,000	432,887,000	500,755,000	537,408	496,694,000	429,689,000	534,887,000	497,263,000	471,315,000	400,529,000	367,885,000	386,295,000	346,456,000	312,195,000	336,869,000	285,730,000	252,693,000	235,237,000	266,135,000	241,781,000	235,457,000	219,142,000	247,802,000
assets held for sale																											683,400,000	682,000,000																																																		9,601,000	9,403,000	24,534,000	58,416,000	65,186,000
liabilities held for sale																											88,600,000	97,200,000
deferred tax assets																													2,160,900,000	2,217,900,000	2,277,400,000																																															44,966,000	55,732,000	33,730,000	41,242,000	149,187,000	145,006,000	90,568,000	86,880,000
deferred tax liabilities																													1,114,600,000	1,160,800,000	1,331,100,000
current portion of notes payable and other financing arrangements																																3,200,000	573,200,000	559,900,000	561,500,000	4,700,000	4,900,000	4,800,000	4,900,000	4,800,000	5,171,000
notes payable and other financing arrangements																																5,935,000,000	5,938,300,000	5,954,000,000	5,952,700,000	6,512,700,000	6,529,600,000	6,538,300,000	6,535,600,000	6,521,500,000	6,529,275,000							592,433,000	694,894,000	726,388,000	711,831,000
long-term deferred tax liability																																					98,700,000	105,600,000	117,800,000	124,900,000	136,761,000	138,403,000	130,564,000	50,656,000	90,357,000	139,092,000	200,901,000	232,554,000	302,483,000	313,341,000	156,667,000		217,272,000	249,577,000	282,904,000	324,264,000	248,644,000	238,175,000	196,784,000	218,504,000	200,950,000		207,492,000	248,898,000	240,618,000	289,654	310,962,000	345,784,000	356,017,000	440,164,000	501,452,000	523,392,000	521,525,000	558,743,000	588,784,000	614,586,000	643,645,000	653,433,000	691,395,000	736,255,000	762,282,000	856,297,000	882,021,000	895,851,000	921,771,000
due from unconsolidated joint business																																								314,500,000	319,788,000	323,714,000	311,956,000	283,360,000	269,999,000	286,897,000	278,316,000	252,662,000	263,465,000	249,996,000	267,429,000		268,395,000	268,965,000	266,841,000	257,351,000	228,724,000	231,582,000	184,871,000	230,610,000	222,459,000		250,143,000	205,228,000	193,789,000	193,279	198,206,000	180,666,000	206,925,000	196,542,000	184,221,000	159,560,000	166,686,000	161,272,000	162,468,000	151,754,000	168,708,000	157,319,000	164,862,000	140,975,000	141,059,000	141,543,000	140,945,000	137,948,000	137,451,000
biogen idec inc. shareholders’ equity
total biogen idec inc. shareholders’ equity																																												10,809,010,000	10,427,696,000	9,561,299,000	9,136,711,000	8,620,242,000	8,125,092,000	7,901,549,000	7,339,010,000		6,961,523,000	6,659,552,000	6,268,297,000	6,305,901,000	6,425,499,000	6,229,148,000	5,977,050,000	5,604,159,000	5,396,506,000		5,170,806,000	5,909,372,000	6,221,530,000	6,564,189	6,212,538,000
current portion of notes payable and line of credit																																														3,386,000	3,550,000	3,494,000	3,385,000	3,188,000	203,317,000		453,379,000	453,209,000	453,045,000	453,361,000						11,300,000	10,096,000	19,115,000	19,762,000	15,452	14,697,000	26,488,000	27,667,000
reverse repurchase agreements																																																			2,968,000,000
2.2
3.1
3.2
3.3
3.4
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8+
4.9
10.1
10.2
10.3†
10.4†
10.5
10.6*
10.7*
10.8*
10.9*
10.10*
exhibit no.
10.11*
10.12*
10.13*
10.14*
10.15*
10.16*
10.17*
10.18*
10.19*
10.20*
10.21*
10.22*
10.23*
10.24*
10.25*
10.26*
10.27*
10.28*
10.29*
10.30*
10.31*
10.32*
10.33*
10.34*
notes payable, line of credit and other financing arrangements																																																					687,396,000	658,442,000	641,568,000	626,012,000	1,060,808,000
current portion of notes payable, line of credit and other financing arrangements																																																									3,292,000	3,422,000	131,981,000	134,779,000	137,153,000
notes payable and line of credit																																																										1,060,639,000	1,062,986,000	1,065,613,000	1,066,379,000	1,068,800,000	1,069,725,000	1,076,201,000	1,080,207,000	1,085,844	1,085,607,000
biogen idec inc. shareholders’ equity:
financial assets:
marketable securities — current																																																														197,800,000
marketable securities — non-current																																																														560,000,000
total financial assets																																																														1,384,600,000
borrowings:
total borrowings																																																														1,080,100,000
working capital:
current assets																																																														2,131,100,000
current liabilities																																																														-824,500,000
total working capital																																																														1,306,700,000
•																																																														2,077,600,000
liabilities and shareholders’ equity
shareholders’ equity:
noncontrolling interest																																																															40,484,000	41,222,000	40,352,000	33,621	33,167,000	32,560,000
total shareholders’ equity																																																															5,211,290,000	5,950,594,000	6,261,882,000			6,020,254,000	5,806,083,000	5,768,478,000	5,522,931,000	5,532,708,000	5,534,295,000	4,992,699,000	4,636,699,000	7,347,166,000	7,149,778,000	6,894,874,000	7,008,591,000	7,142,842,000	6,905,876,000	6,797,827,000	6,745,814,000	6,780,959,000
total liabilities and shareholders’ equity																																																															7,502,150,000	8,217,323,000	8,551,854,000			8,575,206,000	8,478,991,000	8,535,208,000	8,172,826,000	8,170,653,000	8,628,815,000	7,816,375,000	8,935,715,000	8,709,580,000	8,552,808,000
collateral received for loaned securities																																																																					29,991,000
loaned securities																																																																					29,446,000	158,971,000	191,244,000	140,981,000	204,433,000
collateral payable on loaned securities																																																																					29,991,000	178,129,000	146,956,000	124,693,000	208,209,000
cash collateral received for loaned securities																																																																						178,129,000	146,956,000	124,693,000	208,209,000
accumulated deficit																																																																							-103,137,000	-199,204,000	-352,169,000	-553,080,000	-666,955,000	-821,215,000	-860,827,000	-954,991,000	-1,104,681,000	-928,178,000	-1,021,644,000	-802,311,000	-793,384,000	-808,423,000	-801,094,000
tender obligation																																																																											2,990,030,000
tender offer obligation																																																																											-2,990,297,000
property and equipment																																																																													1,280,385,000	1,246,116,000	1,227,296,000	1,191,968,000	1,174,396,000	1,093,680,000	1,150,420,000	1,561,918,000	1,525,225,000
deferred stock-based compensation																																																																																	-42,894,000	-53,836,000	-66,466,000	-82,105,000	-36,280,000
deferred revenue																																																																														6,730,000	19,415,000	19,226,000	16,928,000	18,603,000	16,389,000	20,778,000	13,695,000
convertible preferred stock, par value 0.001 per share...
less treasury stock, at cost																																																																														393,318,000	113,142,000	137,268,000		586,755,000	646,677,000	526,742,000
marketable securities available-for-sale																																																																																313,490,000	282,585,000	314,906,000	289,053,000	875,438,000	1,109,624,000
shareholders’ equity
accounts receivable, less allowances																																																																																	265,742,000
current taxes payable																																																																																	200,193,000				129,350,000
less treasury stock, at cost; 5,751 and 8,766 shares at december 31, 2005 and 2004, respectively																																																																																	222,760,000

Cashflow Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2010-12-31	2009-06-30	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31

cash flow from operating activities:
net income	319,500,000	-48,900,000	466,500,000	634,800,000	240,500,000	266,700,000	388,500,000	583,600,000	393,400,000	248,900,000	-68,300,000	593,300,000	387,600,000	549,500,000	1,134,900,000	1,058,700,000	218,500,000	-20,500,000	318,000,000	1,025,500,000	404,600,000	357,600,000	703,900,000	1,606,400,000	1,392,600,000	1,439,700,000	1,545,900,000	1,494,100,000	1,408,800,000	944,900,000	1,442,900,000	915,000,000	1,171,200,000	-166,300,000	1,226,100,000	862,800,000	747,500,000	647,900,000	1,030,200,000	1,048,400,000	969,200,000	828,708,000	1,019,493,000	924,825,000	820,174,000	723,132,000	479,728,000	487,616,000	490,670,000	426,749,000	398,399,000	387,141,000	302,366,000	897,946,179	391,464,000	206,654,000	206,788,000	206,628,000	163,097,000	201,150,000	119,381,000	186,140,000	131,501,000	108,556,000	156,599,000	-170,613,000	122,969,000	55,562,000	27,185,000	34,506,000	43,458,000
adjustments to reconcile net income to net cash flow from operating activities:
depreciation and amortization	204,400,000	200,200,000	202,200,000	194,300,000	183,200,000	184,000,000	182,800,000	158,900,000	147,500,000	140,100,000	125,000,000	117,400,000	112,300,000	119,800,000	120,700,000	134,800,000	143,100,000	134,700,000	133,200,000												346,500,000	171,500,000	168,900,000				512,000,000	177,400,000	180,200,000	175,400,000	149,700,000	156,300,000	151,577,000	144,586,000	147,937,000	164,139,000	190,963,000	147,477,000	128,427,000	97,453,000	94,203,000	90,624,000	83,945,000														123,230,000	97,524,000	109,751,000	98,822,000	96,111,000
excess and obsolescence charges related to inventory	4,800,000	15,300,000	-400,000	7,000,000	7,300,000	33,200,000	24,300,000	16,900,000	27,500,000	62,300,000	25,300,000	19,400,000	17,400,000	14,600,000	16,000,000	24,100,000	281,500,000
amortization of acquired inventory step-up	107,600,000	75,400,000	61,500,000	52,500,000	51,400,000	44,900,000	50,900,000
share-based compensation	84,000,000	59,600,000	75,300,000	74,900,000	81,000,000	75,100,000	72,700,000	70,600,000	72,800,000	54,900,000	62,200,000	71,500,000	75,600,000	67,200,000	63,600,000	55,700,000	67,600,000	58,800,000	55,700,000	54,100,000	70,000,000	49,000,000	33,500,000	48,100,000	67,700,000	38,400,000	45,900,000	52,300,000	45,700,000	38,500,000	37,300,000	38,300,000	43,400,000	30,600,000	30,100,000	30,300,000	37,000,000	37,000,000	33,700,000	38,800,000	45,300,000	29,863,000	37,860,000	41,614,000	52,063,000	37,516,000	46,340,000	37,464,000	30,630,000	36,757,000	27,911,000	28,071,000	32,396,000	167,691,406	78,892,000		36,692,000	33,118,000	34,529,000
contingent consideration	20,500,000	5,200,000	5,600,000	13,200,000	9,600,000	3,900,000								-195,400,000	-2,100,000	-4,500,000	-7,100,000	-1,600,000	-15,600,000	300,000	-33,800,000	-62,800,000	-29,000,000	10,100,000	-4,600,000	2,600,000	-57,800,000	-20,000,000	11,500,000	79,300,000
deferred income taxes	23,600,000	166,900,000	253,800,000	-31,300,000	-27,800,000	-58,400,000	-52,600,000	-87,000,000	39,900,000	71,900,000	-206,800,000	-106,400,000	-64,500,000	-28,800,000	-92,300,000	-48,500,000	1,000,000	323,300,000	-127,300,000	-607,800,000	-15,000,000	-62,900,000	31,700,000	143,300,000	36,900,000	38,700,000	-43,200,000	-156,400,000	228,000,000	153,100,000	12,600,000	-110,500,000	53,100,000	131,400,000	-19,200,000	-96,600,000	76,100,000	-118,200,000	-26,600,000	-39,100,000	8,900,000	40,202,000	-95,155,000	-107,386,000	16,739,000	-66,948,000	-79,558,000	-48,140,000	-51,522,000	-66,525,000	-43,027,000	-39,955,000	-3,876,000	-81,348,756	-42,772,000	-81,958,000	-42,834,000	-21,940,000	7,183,000	-41,189,000	-22,194,000	-23,187,000	5,015,000	-26,560,000	-33,679,000	-19,566,000	-26,532,000	16,672,000	-32,651,000	-73,731,000	-25,829,000
loss on strategic investments	-19,000,000	-14,400,000	500,000	-7,700,000	40,900,000	78,700,000	-38,900,000	30,300,000	31,300,000	1,400,000	302,500,000	-106,400,000	79,600,000	105,600,000	-109,000,000	78,200,000	191,100,000	116,300,000	426,900,000	-154,000,000	437,600,000
other	28,000,000	19,000,000	33,300,000	9,300,000	6,700,000	64,500,000	30,100,000	39,600,000	25,400,000	49,600,000	38,100,000	29,100,000	31,400,000	60,400,000	35,600,000	68,900,000	43,300,000	1,200,000	88,600,000	40,700,000	71,700,000	21,100,000	24,800,000	39,600,000	45,700,000	-18,200,000	-3,700,000	40,400,000	50,700,000	-900,000	-110,600,000	16,300,000	26,100,000	35,200,000	53,400,000	55,400,000	18,100,000	57,800,000	13,600,000	40,000,000	-20,200,000	50,636,000	37,372,000	27,113,000	-32,921,000	7,263,000	-71,476,000	5,918,000	-9,053,000	-33,442,000	27,113,000	8,003,000	-29,073,000														1,193,000			-536,000	-1,369,000
changes in operating assets and liabilities, net of effects of business acquired:
accounts receivable	-33,700,000	27,800,000	245,400,000	10,500,000	-181,000,000	94,700,000	115,300,000	-31,400,000	43,700,000	137,800,000	-98,300,000	-55,400,000	77,200,000	-93,900,000	-42,200,000	20,200,000	-87,500,000	167,000,000	-53,700,000	174,300,000	37,200,000	138,500,000	133,100,000	-30,400,000	-238,400,000	71,200,000	500,000	133,700,000	-136,600,000	48,800,000	-66,800,000	-53,200,000	-134,000,000	-209,800,000	75,400,000	-105,500,000	-195,700,000	-3,300,000	-173,100,000	95,000,000	-160,000,000	92,608,000	-24,701,000	89,380,000	-128,287,000	8,724,000	-197,685,000	-34,172,000	-110,142,000	-75,546,000	29,244,000	78,308,000	-89,066,000	-99,154,281	-63,842,000	37,772,000	-9,035,000	-31,599,000	-54,703,000	-12,978,000	-16,724,000	-34,357,000	-6,642,000	-18,164,000	2,036,000	-11,396,000	-9,485,000	-5,245,000	-7,635,000	17,797,000	1,335,000
due from anti-cd20 therapeutic programs	103,400,000	-48,800,000	-16,000,000	-66,200,000	70,400,000	-12,200,000	-800,000	-55,800,000	40,700,000	-7,700,000	9,800,000	-44,300,000	37,600,000	-16,000,000	20,600,000	-46,500,000	22,900,000	-12,300,000	22,200,000	-52,500,000	43,800,000	113,700,000	-86,100,000	70,500,000	78,600,000
inventory	116,200,000	-29,400,000	-7,400,000	-89,900,000	62,000,000	-66,400,000	-19,200,000	-110,500,000	-77,700,000	-96,000,000	30,200,000	-93,000,000	27,900,000	18,100,000	-95,000,000	-100,700,000	-142,600,000	-139,800,000	-128,800,000	-81,300,000	-112,500,000	-45,700,000	-82,400,000	-126,000,000	-62,200,000	-66,500,000	-61,400,000	-20,300,000	129,000,000	-20,200,000	8,200,000	-42,700,000	2,600,000	75,800,000	-85,000,000	-39,100,000	-46,200,000	-10,500,000	-26,800,000	-39,700,000	-88,600,000	-24,013,000	-69,093,000	-59,787,000	-21,507,000	-55,709,000	-16,980,000	-53,643,000	-68,362,000	-60,809,000				-4,543,311	-14,353,000	-19,828,000	-6,189,000	-21,843,000	-6,344,000	-12,326,000	-18,785,000	-28,890,000	-23,191,000	-13,664,000	605,000	-8,071,000	-15,507,000	21,748,000	-4,268,000	-19,763,000	-30,449,000
accrued expense and other current liabilities	-243,200,000	203,800,000	286,000,000	-18,200,000	-300,500,000	108,800,000	31,400,000	61,500,000	-177,100,000	-495,500,000	421,000,000	167,900,000	-295,000,000	-745,700,000	-1,700,000	1,095,600,000	-461,600,000	147,900,000	-54,900,000	95,200,000	-283,600,000
income tax assets and liabilities	18,400,000	-194,000,000	-229,400,000	-603,800,000	69,100,000	16,400,000	69,800,000	-5,500,000	-2,200,000	-184,200,000	-32,400,000	-147,400,000	65,000,000	-42,100,000	-34,300,000	-167,800,000	101,900,000	-29,700,000	89,000,000	106,700,000	64,800,000	-82,800,000	-489,300,000	281,600,000	223,000,000	-48,500,000	-242,300,000	136,600,000	170,300,000	6,100,000	132,200,000	-74,200,000	257,600,000	1,133,400,000	285,200,000	80,400,000	-195,100,000
other changes in operating assets and liabilities	-89,000,000	-68,100,000	-104,400,000	-22,000,000	-53,500,000	-113,000,000	37,300,000	-46,900,000	-56,100,000	-2,500,000	-15,900,000	41,300,000	-96,800,000	-107,900,000	149,900,000	79,600,000	-213,600,000	-56,900,000	9,700,000	-16,400,000	-80,900,000	-40,100,000	-106,900,000	-8,600,000	18,500,000		19,300,000	90,800,000	-171,100,000		-89,700,000	28,700,000	-20,000,000		-62,900,000	-153,000,000	-34,300,000		12,000,000	35,300,000	14,800,000		-55,285,000	3,337,000	-69,711,000	31,407,000	-75,338,000	129,402,000	33,654,000	35,212,000	38,262,000	-50,615,000	-20,036,000
net cash flow from operating activities	645,500,000	511,900,000	1,272,500,000	160,900,000	259,300,000	760,900,000	935,600,000	625,800,000	553,200,000	12,500,000	592,400,000	487,000,000	455,300,000	-175,000,000	661,000,000	736,500,000	161,800,000	838,300,000	805,300,000	1,227,300,000	769,000,000
cash flow from investing activities:
purchases of property, plant and equipment	-51,200,000	-43,900,000	-46,200,000	-26,600,000	-37,100,000	-39,300,000	-35,000,000	-33,500,000	-45,900,000	-65,200,000	-74,200,000	-71,000,000	-66,600,000	-86,400,000	-59,100,000	-36,900,000	-57,900,000	-51,600,000	-42,000,000	-71,900,000	-92,600,000	-86,000,000	-84,100,000	-105,000,000	-149,700,000	-110,400,000	-90,100,000	-186,900,000	-127,100,000	-225,900,000	-163,200,000	-186,800,000	-194,700,000	-230,600,000	-229,100,000	-197,700,000	-210,000,000	-182,100,000	-170,300,000	-136,800,000	-126,900,000	-186,115,000	-229,197,000	-129,858,000	-97,830,000	-64,002,000	-54,306,000	-80,188,000	-54,151,000	-33,289,000	-58,064,000	-72,896,000	-54,551,000	-172,930,780	-71,721,000	-53,993,000	-64,868,000	-71,062,000	-86,031,000	-108,356,000	-58,502,000	-79,846,000	-37,402,000
proceeds from sales and maturities of marketable securities	625,200,000									0	5,698,600,000	1,275,500,000	406,700,000	566,300,000	1,643,200,000	917,900,000	543,600,000	1,377,300,000	575,400,000	633,500,000	819,200,000	2,058,700,000	1,360,800,000	1,490,600,000	2,389,300,000	2,139,400,000	611,800,000	1,766,600,000	1,489,200,000	1,179,000,000	1,192,000,000	2,733,800,000	4,068,900,000	1,093,300,000	888,100,000	1,700,200,000	1,884,300,000	2,193,100,000	2,362,200,000	1,642,500,000	1,181,100,000	699,626,000	2,387,857,000	601,954,000	373,563,000	560,013,000	757,512,000	620,511,000	75,201,000	4,329,506,000	489,450,000	599,497,000	824,434,000	2,666,203,637	1,637,562,000				917,972,000			1,606,127,000	803,675,000	319,042,000	445,040,000
purchases of marketable securities	-748,800,000	-1,167,300,000								0	-1,020,400,000	-2,799,100,000	-1,321,200,000	-642,600,000	-494,300,000	-1,178,100,000	-1,133,500,000	-1,436,100,000	-745,700,000	-713,600,000	-913,300,000	-1,748,600,000	-895,200,000	-2,069,200,000	-1,684,700,000	-1,200,500,000	-1,977,000,000	-1,250,100,000	-825,000,000	-1,601,000,000	-1,319,500,000	-2,855,100,000	-1,919,200,000	-1,261,300,000	-1,557,900,000	-1,279,300,000	-1,256,700,000	-2,281,500,000	-1,798,400,000	-1,918,900,000	-1,914,400,000	-1,994,758,000	-2,825,096,000	-1,722,088,000	-322,958,000	-1,121,395,000	-666,211,000	-855,635,000	-457,294,000	-1,160,680,000	-938,409,000	-576,842,000	-677,092,000	-1,987,022,231	-1,869,415,000	-1,362,768,000	-740,897,000	-628,500,000	-431,659,000	-743,726,000	-333,147,000	-989,821,000	-878,550,000	-352,644,000	-268,241,000
acquired in-process research and development	-35,000,000																	0	0			0	0	0	75,000,000					0	27,500,000	75,000,000	10,000,000	240,000,000	0																												18,405,000
acquisitions of intangible assets		-16,300,000	-5,300,000	0	-10,000,000	-27,000,000	-95,000,000	-9,100,000	-75,000,000	0	-13,400,000	-16,000,000	-5,000,000	-1,000,000	0			-16,900,000				-15,000,000	0	0	-37,000,000					0	0			-65,000,000	-50,100,000	-5,100,000	-855,200,000	-1,200,000
proceeds from sales of strategic investments	500,000	100,000				48,000,000	39,200,000	1,900,000	55,600,000	13,400,000	3,000,000	69,400,000	33,800,000					2,300,000	0	0	91,200,000	74,400,000	0	0	500,000	3,300,000	166,300,000
net cash flow from investing activities	-209,500,000	-1,231,700,000	-35,100,000	-57,000,000	-47,300,000	-18,600,000	-1,181,100,000	466,500,000	-66,000,000	-652,300,000	-1,742,200,000	-753,500,000	-953,000,000	-141,100,000	1,672,200,000	693,500,000	-648,000,000				-64,700,000
cash flow from financing activities:
payments related to issuance of stock for share-based compensation arrangements	-55,100,000	3,000,000	5,200,000	6,100,000	-24,300,000	3,500,000	6,000,000	6,100,000	-46,900,000	3,700,000	6,600,000	5,500,000	-60,100,000	3,900,000	5,700,000	9,300,000	-20,800,000	7,600,000	5,900,000	12,900,000	-27,100,000	7,200,000	7,400,000	10,400,000	-29,600,000		6,700,000	8,600,000	-32,200,000	4,600,000	7,600,000	6,900,000	-21,200,000	5,400,000	7,100,000	7,700,000	-25,500,000
net cash flow from financing activities	-43,800,000	-137,000,000	-130,200,000	-11,700,000	-23,000,000	7,900,000	-6,600,000	-245,200,000	-439,600,000	-646,100,000	848,600,000	-9,800,000	-43,400,000	-7,400,000	-1,251,900,000	-471,500,000	-16,500,000
net increase in cash and cash equivalents	392,200,000	-856,800,000	1,107,200,000	92,200,000	189,000,000	750,200,000	-252,100,000	847,100,000	47,600,000	-1,285,900,000	-301,200,000	-276,300,000	-541,100,000	-323,500,000	1,081,300,000	958,500,000	-502,700,000	735,400,000	-174,800,000	510,100,000	-80,700,000	-934,600,000	-184,200,000	-197,600,000	-335,100,000	552,200,000	640,000,000	-522,500,000	1,019,000,000	-1,166,900,000	1,141,900,000	-2,840,700,000	2,535,100,000	40,700,000	362,000,000			273,700,000	722,200,000	246,300,000	-192,400,000	-2,765,537,000	2,813,095,000	-209,680,000	311,022,000	38,106,000	225,494,000	29,008,000	-271,792,000	96,456,000			-221,021,000	185,032,281	162,304,000	-390,304,000	547,551,000	-224,330,000	29,030,000			830,524,000	119,348,000	246,695,000	70,061,000	-191,368,000	-32,303,000	271,676,000	-341,908,000	361,957,000	66,996,000
effect of exchange rate changes on cash and cash equivalents	-18,000,000	2,500,000	-3,200,000	68,300,000	34,300,000	-74,400,000	42,400,000	-12,600,000	-23,100,000	47,900,000	-28,700,000	-4,100,000	20,000,000	67,200,000	-52,300,000	-61,200,000	-9,400,000	-15,800,000	-25,400,000	14,400,000	-33,000,000	41,000,000	24,100,000	-8,800,000	12,700,000	17,600,000	-19,500,000	2,700,000	-400,000	4,800,000	-5,400,000	-17,100,000	-900,000	-15,000,000	16,600,000	29,900,000	7,900,000	-32,000,000	600,000	-15,000,000	15,100,000	-15,442,000	-6,170,000	13,707,000	-37,895,000	-3,510,000	545,000	6,296,000	997,000	-3,875,000	3,768,000	-6,353,000	4,618,000	-7,368,149	2,115,000	1,988,000	-3,343,000	2,324,000	-193,000	-542,000	-348,000	117,000	215,000	88,000
cash and cash equivalents, beginning of the period	3,008,500,000		0	0	2,375,000,000		0	0	1,049,900,000		0	0	3,419,300,000		0	0	2,261,400,000		0	0	1,331,200,000		0	0	2,913,700,000		0	0	1,224,600,000		0	0	1,573,800,000		0	0	2,326,500,000		0	0	1,308,000,000		0	0	1,204,924,000	0	602,562,000	0	0	570,721,000	0	0	514,542,000		622,385,000		0	0	659,662,000		0	0	661,377,000		0	0	568,168,000		0	0	209,447,000
cash and cash equivalents, end of the period	3,382,700,000		1,104,000,000	160,500,000	2,598,300,000		-209,700,000	834,500,000	1,074,400,000		-329,900,000	-280,400,000	2,898,200,000		1,029,000,000	897,300,000	1,749,300,000		-200,200,000	524,500,000	1,217,500,000		-160,100,000	-206,400,000	2,591,300,000		620,500,000	-519,800,000	2,243,200,000		1,136,500,000	-2,857,800,000	4,108,000,000		378,600,000	245,500,000	924,000,000		722,800,000	231,300,000	1,130,700,000		2,806,925,000	-195,973,000	1,478,051,000	34,596,000	828,601,000	35,304,000	-270,795,000	663,302,000	-5,088,000	158,672,000	298,139,000		786,804,000		544,208,000	-222,006,000	688,499,000		-1,174,255,000	830,641,000	780,940,000		69,490,000	-190,761,000	535,865,000		-341,908,000	361,957,000	276,443,000
impairment of intangible assets		4,400,000	0			40,000,000												0	43,400,000
impairment of rou asset
gain on sale of priority review voucher						0	0
acquisition of reata, net of cash acquired										-590,500,000
acquisition of hi-bio, net of cash acquired						0
proceeds from sale of equity interest in samsung bioepis						0	0			0	0			0
proceeds from sale of priority review voucher						0	-14,400,000
proceeds from borrowings		0	-300,000							0												100,000	0																			-436,000																		617,000
repayments of borrowings		0	0																																																					0	0	-12,474,000	-1,500,000,000	0
net (distribution) contribution to noncontrolling interest										8,100,000	2,500,000	1,500,000	200,000	200,000	100,000	11,900,000	200,000
contingent consideration payments
cash and cash equivalents, beginning of the year
cash and cash equivalents, end of the year
cash paid for contingent consideration
repayment of borrowings							0																0								0																								-10,867,000
loss on equity method investment																		-17,700,000	-1,100,000	-34,300,000	18,200,000	-18,000,000
gain on sale of equity interest in samsung bioepis														0	0
gain on sale of building														0
proceeds from sale of building														0
purchase of treasury stock																																										-2,001,810,000	-2,955,997,000					-359,285,000	0	-41,023,000	-53,220,000	-446,780,000	-463,171,000		-57,631,000	-179,171,000	0							0	-319,902,000				0	-154,115,000	-168,475,000
repayments of borrowings and premiums paid
amortization of inventory step-up									44,100,000
repayment of borrowings and premiums paid									-400,000,000
proceeds from divestiture of hillerød, denmark manufacturing operations																		0	0	0	28,100,000					0
loss on equity method investments															0	-5,900,000	3,300,000
purchases of treasury stock															-250,000,000				-750,000,000	-450,000,000	-600,000,000		-1,250,000,000	-2,808,900,000	-2,220,200,000	-2,093,100,000	-717,900,000	-2,401,500,000	-655,800,000	-1,352,600,000	0	-2,750,000,000	-250,000,000	0	0	-781,800,000	-583,600,000
changes in operating assets and liabilities, net:
loss on divestiture of hillerød, denmark manufacturing operations																										-40,200,000
purchase of sangamo therapeutics, inc. stock																						0	0
purchase of denali therapeutics inc. stock																						0
purchase of sage therapeutics, inc. stock
repayments of borrowings and premiums paid on debt exchange
proceeds from sale of equity in samsung bioepis
proceeds from the sales of strategic investments
repayment of borrowings and premiums paid on debt exchange																			0	-700,000	-169,300,000
contingent consideration paid related to fumapharm ag acquisition																											0	0	-300,000,000		-300,000,000	-300,000,000	-600,000,000
acquisition of nightstar therapeutics plc, net of cash acquired																										0	0
net cash flow used in financing activities																		9,800,000	-746,500,000	-564,500,000	-785,000,000
net cash flow used in investing activities																			-233,600,000
cash proceeds from settlement of swap
net distribution to noncontrolling interest																			0								0			500,000	2,000,000
gain on interest rate swap
depreciation, amortization and impairments																					146,900,000		134,000,000	112,900,000	119,900,000	113,000,000	329,500,000	117,000,000	121,100,000
cash flows from operating activities:
adjustments to reconcile net income to net cash flows from operating activities:
loss on divestiture of hillerod, denmark manufactuing operations
unrealized loss on strategic investments																						-723,600,000	81,500,000					175,800,000	-375,000,000
accrued expenses and other current liabilities																						-218,700,000	814,300,000	-94,000,000	-347,400,000	349,300,000	107,000,000	-77,700,000	-138,400,000	364,800,000	87,400,000	135,100,000	-121,800,000	277,100,000	-52,200,000	231,900,000	-684,200,000	793,300,000	-60,900,000	18,500,000	-180,800,000	248,732,000	-4,603,000	35,538,000	-205,467,000	141,069,000	-171,368,000			-180,910,000	52,102,000	134,004,000	-82,031,000	130,857,623	22,950,000	-6,970,000			65,682,000	8,895,000	24,258,000	-14,187,000	13,494,000	78,683,000	17,716,000	-22,635,000	-59,952,000	241,000	17,669,000	77,371,000	-7,727,000
net cash flows from operating activities																						-367,100,000	1,181,100,000	1,948,500,000	1,467,300,000	1,960,200,000	1,694,900,000	1,964,000,000	1,459,500,000	1,895,400,000	1,735,900,000	1,099,300,000	1,457,100,000	1,518,300,000	1,628,300,000	1,169,200,000	235,200,000	1,576,600,000	986,600,000	995,800,000	963,400,000	1,040,395,000	895,448,000	1,047,220,000	733,037,000	990,593,000	104,626,000	671,922,000	625,212,000	178,939,000	541,784,000	635,581,000	194,625,000	1,623,479,383	529,301,000	409,292,000	512,193,000	276,022,000	366,985,000	345,862,000	210,426,000	202,018,000	262,329,000	241,805,000	259,838,000	183,372,000	156,253,000	274,740,000	173,095,000	228,782,000	212,886,000
cash flows from investing activities:
purchase of ionis pharmaceuticals, inc. stock																														0	800,000
proceeds from divesiture of hillerod, denmark manufacturing operations
investment in samsung bioepis
net cash flows from investing activities																						-166,400,000	-52,400,000	-832,700,000	442,900,000			-110,800,000	238,800,000		-619,100,000	-1,148,500,000	1,346,600,000												-502,771,000		5,993,000			155,941,000			618,000		-303,220,000		-99,470,000	-250,223,000	449,577,000	-616,635,000					121,491,000	-385,374,000	-272,212,000	-70,944,000	-534,294,000	1,027,693,000	-4,714,000
cash flows from financing activities:
net contribution (distribution) to noncontrolling interest
net cash flows from financing activities																						-401,100,000	-1,312,900,000					-2,375,700,000	-679,300,000		25,100,000	-2,791,500,000	-268,600,000					-721,200,000	-300,600,000	-13,400,000	47,400,000	-1,998,403,000	2,907,584,000	-3,537,000	80,756,000		114,875,000								-63,777,000												83,656,000	67,880,000	19,291,000	-894,518,000	-141,176,000
proceeds from settlement of net investment hedge
unrealized (gain) loss on strategic investments																									62,000,000
net cash flows used in financing activities																									-2,245,300,000	-2,116,400,000									-19,500,000	-751,000,000	-901,400,000											-318,522,000	-170,763,000	-238,424,000	-28,250,000	-417,440,000	-416,264,000	-1,782,908,155
other liabilities																																																											9,957,000	13,652,000	26,437,000	-1,382,000	2,587,000
contingent consideration related to fumapharm ag acquisition																																		-300,000,000	-300,000,000	-300,000,000	-300,000,000	-300,000,000	-300,000,000	-300,000,000	-300,000,000	-300,000,000	-300,000,000	0	-250,000,000
net contribution (distribution) to noncontrolling interests
net cash contribution to bioverativ, inc.
net cash flows used in investing activities																																			-1,246,800,000	-202,600,000	-744,200,000	-581,700,000	36,200,000	-736,100,000	-1,203,200,000	-1,807,529,000	-989,937,000					-324,392,000			-522,390,000												-167,382,000
loss on assets and liabilities held for sale																												-2,300,000	115,500,000
other assets																																																						-12,561,565	-5,537,000	-21,187,000	32,325,000	-4,716,000	-2,711,000	71,495,000	-58,372,000	5,950,000	-18,835,000	-24,264,000	219,000
net cash contribution to bioverativ inc.																																			0
acquisitions of businesses, net of cash acquired
depreciation, amortization and acquired in-process research and development																																			177,400,000
net cash contribution to bioverativ																																					-302,700,000
net decrease in cash and cash equivalents																																					-1,410,400,000														-8,856,000
proceeds from issuance of stock for share-based compensation arrangements																																						8,500,000	11,300,000	9,400,000	14,500,000	8,691,000	10,782,000	9,113,000	25,614,000	11,114,000	22,363,000	17,365,000	17,185,000	21,817,000	15,197,000	19,001,000	24,080,000	183,405,553	24,387,000
excess tax benefit from share-based compensation																																																						13,142,284
changes in other tax assets and liabilities
acquisitions of business, net of cash acquired																																											0	0	-198,798,000	0	-25,000,000				0
excess tax benefit from share-based awards																																							2,900,000
current taxes payable																																								-376,800,000	225,100,000			-52,000,000	154,017,000
excess tax benefit from stock options																																									8,300,000		1,088,000	3,261,000	66,429,000	4,484,000	79,456,000								-2,800,000	-566,000	-8,976,000	-10,822,000	-7,626,000	-38,266,000	-21,560,000	-4,647,000	-5,193,000
other long-term liabilities and taxes payable
due from unconsolidated joint business																																																						-28,642,171	8,719,000	-10,383,000	-12,321,000	-24,661,000	7,126,000	-5,414,000	1,196,000	-10,714,000	16,954,000	-11,389,000	7,543,000	-23,887,000	84,000	484,000	-598,000	-2,997,000	-497,000
acquisition of tysabri rights																																																0
acquisitions of businesses
repayment of borrowings under senior notes																																																0	-2,340,000	-450,000,000
purchases of reverse repurchase agreements																																																		-2,968,000,000
proceeds from borrowings under line of credit facility																																																		200,000,000
acquisition of stromedix, inc., net of cash acquired																																																					-72,401,000
depreciation and amortization of property, plant and equipment, and intangible assets
fair value adjustment of contingent consideration
excess tax benefit from shared-based compensation
write-down of inventory to net realizable value																																																						11,798,082	11,475,000	7,378,000	12,634,000	5,452,000	4,386,000	2,020,000	4,745,000	8,117,000	6,717,000	381,000	559,000	8,751,000	3,298,000	18,333,000	16,102,000	8,308,000	41,304,000
impairment of marketable securities, investments and other assets																																																						20,826,681	10,002,000
non-cash interest income, foreign exchange remeasurement gain, net and other
realized (gain) loss on sale of marketable securities and strategic investments
other liabilities and taxes payable																																																						17,650,436	-90,748,000	54,291,000
acquisitions																																																						-72,436,024
acquisition of a variable interest entity																																																						-84,867,048
proceeds from the sale of property, plant and equipment
purchases of intangible assets
purchases of other investments																																																						-4,486,501	-35,202,000		-5,649,000	-2,390,000	-9,221,000		-3,704,000	-2,932,000	-12,886,000		-1,275,000	-2,211,000	-2,094,000
proceeds from the sale of strategic investments
collateral received under securities lending																																																							29,991,000	148,138,000	-31,173,000	-22,263,000	83,516,000
change in cash overdraft																																																						11,778,414	7,525,000
acquisition of noncontrolling interests
net distributions to noncontrolling interests
net proceeds from financing arrangement for the sale of the san diego facility
repayments on financing arrangement for the sale of the san diego facility
obligation under securities lending																																																							-29,991,000
depreciation and amortization of property, plant and equipment and intangible assets																																																						353,840,911	248,877,000
realized gain on sale of marketable securities and strategic investments																																																							-15,434,000		9,702,000
(gain) loss on disposal of property, plant and equipment
acquisition of noncontrolling interest
proceeds from the issuance of stock for share-based compensation arrangements
net contributions (to) from noncontrolling interests
non-cash interest income and foreign exchange remeasurement gain																																																						5,806,876
net contributions from noncontrolling interests
acquired in process research and development
cash received upon termination of interest rate swap
(gain) loss on sale of property, plant and equipment
net cash flows from in investing activities
loss on disposal of property, plant and equipment
proceeds from the sale of a strategic equity investment																																																							5,565,000
net distributions to noncontrolling interest
net contributions from noncontrolling interest
non-cash interest income and foreign exchange remeasurement
acquired in process research and development and license
gain on sale of property, plant and equipment
acquisitions, net of cash acquired																																																								0	0	0	-25,000,000	-3,500,000	-50,000,000
proceeds from sale of property, plant and equipment																																																												-143,000	16,742,000	0	70,000	38,274,000	85,000	2,006,000	33,851,000
repayments of long-term debt																																																												0
net capital contribution from noncontrolling interest
supplemental cash flow disclosures:
cash paid during the year for:
interest
income taxes
non-cash financing activity:
conversion of subordinated notes to common and treasury stock
collateral received under securities leading
non-cash interest expense and foreign exchange remeasurement loss																																																							-7,592,000
net income attributable to biogen idec inc.
depreciation and amortization of fixed and intangible assets																																																																87,217,000
noncontrolling interest in subsidiaries
impairment of investments and other assets																																																								30,142,000	16,051,000	6,559,000	8,892,000	18,279,000	653,000	3,053,000	2,460,000		582,000				17,536,000	0	14,588,000
changes in assets and liabilities, net:
adjustments to reconcile net income to net cash flows from operating activities depreciation and amortization of fixed and intangible assets																																																															88,815,000
minority interest in subsidiaries																																																								1,773,000	1,013,000
gain on settlement of license agreements
share based compensation
non-cash interest income and foreign exchange translation gain
facility impairments and (gain) loss on disposition
proceeds from sale of product line
purchase of other investments
proceeds from issuance of stock for share based compensation arrangements																																																								11,454,000	77,500,000	61,221,000	28,311,000	241,744,000
issuance of notes to fumedica
adjustments to reconcile net income to net cash flows from operating activities depreciation and amortization of fixed & intangible assets																																																											106,932,000
in-process research & development																																																									0
non-cash interest expense																																																									-23,439,000	4,009,000	8,142,000
proceeds from sales and maturities of marketable debt securities																																																									743,116,000
proceeds from sale of property, plant, and equipment
change in cash overdrafts																																																									17,179,000	-12,517,000	13,390,000		-9,573,000	-645,000	3,000		-5,842,000	-12,967,000	7,664,000		-4,317,000	-8,511,000	-22,611,000
proceeds from borrowings, net of discounts and expenses																																																									0	104,000	986,876,000
obligations under securities lending																																																									31,173,000	22,263,000	-83,516,000
repayment of long-term debt
net cash flow provided by financing activities																																																									134,828,000	-250,129,000	-787,532,000			64,412,000	24,401,000
adjustments to reconcile net income to net cash flows from operating activities
depreciation and amortization of fixed & intangible assets
accrued expenses and other liabilities
repurchase of senior notes																																																																				-1,000	0
proceeds from line of credit
in process research & development																																																											25,000,000
minority interest of subsidiaries																																																											2,710,000
realized (gain) loss on sale of marketable securities and strategic investment																																																											-5,267,000		-10,668,000
purchase of common stock																																																											-240,219,000
non-cash interest income																																																												1,360,000
acquired in process research & development and license
gain on settlement of license agreement																																																																	0
facility impairment and (gain) loss on sale
proceeds from sale of amevive																																																																0	0
acquired in process research & development
stock-based compensation																																																														29,859,000	29,560,000		36,434,000	42,005,000	23,620,000		2,836,000	8,778,000	7,851,000
facility impairment and (gain) loss on disposition
proceeds from the sale of a strategic investment
net cash flows from (used in) investing activities
proceeds from issuance of stock for share based payment arrangements
proceeds of loan from joint venture partner
repayments of loan to joint venture partner																																																														0	-3,703,000
non-cash financing transaction:
see note 14 “indebtedness” and note 16 “tender offer” for a discussion of non-cash financing transactions that occurred during the six months ended june 30, 2007.
non-cash interest expense and amortization of investment premium																																																															437,000	898,000			-108,000	-7,547,000	1,718,000	8,257,000	16,753,000
realized loss on sale of marketable securities																																																															245,000		662,000	954,000	804,000
gain on sale of long-lived assets
acquisition of syntonix, net of cash acquired																																																															-42,289,000
proceeds from issuance of stock for share-based payment arrangements																																																															22,908,000
adjustments to reconcile net income to net cash flows from
operating activities
acquisition of in process research and development																																																																0
(gain) loss on settlement of license agreements
stock based compensation
realized (gain) loss on investments and other
impairment of property, plant and equipment																																																																				807,000	-3,156,000	0	6,223,000
impairment of investments																																																																			2,107,000
changes in, net of assets and liabilities acquired:
other long-term liabilities																																																																3,525,000	2,426,000	2,149,000	3,605,000	3,191,000	1,356,000	-5,339,000	7,639,000
acquisition of fumapharm, net of cash acquired
acquisition of conforma, net of cash acquired
issuance of stock for stock based compensation arrangements
proceeds from joint venture partner
repayments to joint venture partner
facility impairments and (gain) loss on sale
tax benefit from stock options																																																																	-2,052,000	4,954,000	-15,195,000	13,490,000	-5,694,000	1,131,000	16,438,000
deferred revenue																																																																	-15,456,000	189,000	2,298,000	-1,675,000	2,214,000	-4,389,000	7,083,000
payments for acquisition of fumapharm, net of cash acquired																																																																	0
payments for acquisition of conforma, net of cash acquired																																																																	0
acquisitions of property, plant and equipment																																																																	-54,118,000	-14,092,000	-65,630,000	-102,426,000	-59,734,000	-90,370,000	-65,846,000
issuance of treasury stock for stock-based compensation arrangements																																																																	12,351,000	18,131,000	56,356,000
loan proceeds from joint venture partner																																																																	73,000	10,790,000	4,441,000
cash paid during the period for tax liabilities																																																																	118,372,000
cash paid during the period for interest
acquisition of in process research & development
non-cash interest income and amortization of investment premium
impact of inventory step-up related to inventory sold																																																																		919,000	4,002,000
facility impairments and loss on sale																																																																		-800,000	-298,000	15,208,000
effect of exchange rate changes on cash & cash equivalents
cash flows from operating activities
other current and other assets																																																																			-3,880,000	21,059,000	-4,427,000	835,000	14,758,000
cash flows from investing activities
purchases of marketable securities available-for-sale																																																																			-596,216,000	-211,572,000	-626,988,000	-205,272,000	-290,452,000
proceeds from sales and maturities of marketable securities available-for-sale																																																																			357,877,000	245,659,000	260,093,000	921,543,000	354,839,000
cash flows from financing activities
write-off of acquired in-process research and development
realized gain on sale of marketable securities available-for-sale																																																																							1,679,000
cash received from acquisition of biogen, inc., net of cash paid
restricted cash
proceeds from sale of manufacturing facility																																																																				0	0
issuance of common stock for option exercises and employee stock purchase plan
issuance of treasury stock for option exercises and employee stock purchase plan																																																																						14,523,000	49,910,000
change in cash overdraft.
proceeds from loan
supplemental cash flow data
realized loss on sale of marketable securities available-for-sale																																																																					1,678,000
impact of inventory step-up																																																																					4,235,000	4,541,000	3,537,000
purchases of investments and other assets																																																																					-107,665,000	-6,338,000	-3,255,000
issuance of common stock for stock-based compensation arrangements
loss on sale of manufacturing facility
increase in investments and other assets
proceeds from issuance of notes payable

Biogen Inc(NASDAQ:BIIB)

Biogen Inc
(NASDAQ:BIIB)